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Abstract
The roles of UBXNs in the regulation of antiviral immune responses have not been much
explored. Previous work in our lab identified UBXN1 as a negative regulator of the retinoic acid-

inducible gene-I (RIG-I) like receptors (RLR) pathway and UBXN3B as a positive regulator of
stimulator-of-interferon Genes (STING) -mediated immune responses. In this study, I aimed to
determine the member of UBXNs as a positive regulator of ribonucleic acid (RNA) virus infectioninduced innate immune responses. By using an interferon stimulated response element

(ISRE)-driven luciferase reporter assay that monitors the activity of type I/III interferon (IFN)induced janus kinase (JAK) - signal transducer and activator of transcription proteins (STAT)
signaling, I found that over expressed UBXN6 synergized with RIG-I, IFN-β or IFN-λ to enhance
antiviral immune responses.
I further used small interfering RNA (siRNA) and clustered regularly interspaced short

palindromic repeats (CRISPR)-Cas9 technology to abrogate UBXN6 function, aiming to establish
the function of UBXN6 in viral infection and JAK-STAT signaling. By polymerase chain reaction
(PCR) array I found that UBXN6-deficiency led to a reduction in type I/III IFN-induced gene
expression, which was validated by quantitative reverse transcriptase polymerase chain reaction
(q-RT-PCR). Also, RNA virus replication was increased in UBXN6-deficient when compared to
UBXN6-sufficient cells, which was accompanied by a significant reduction in IFN-β and IFN-λ.
Lastly, I decoded the mechanism by which UBXN6 regulates the JAK-STAT pathway. I observed
that IFN-β-stimulated STAT1 phosphorylation was impaired in UBXN6-deficient cells. By coimmunoprecipitation techniques and mass spectrometry analysis, I identified that following IFN-β
stimulation UBXN6 interacted with protein arginine methyltransferase 5 (PRMT5) that is known to
xiv

interact with JAK1/2. Our results demonstrate that UBXN6 positively regulates JAK1-STAT1/2
signaling to combat viral infections.

xv
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Introduction and Background:
The series of events generated by the host immune system against a virus

determines the fate of viral infection. Both the innate and adaptive responses are induced
after viral infection consecutively. The major component of innate immune responses
includes an anatomical barrier, inflammation, complement cascade, and several types of
white blood cells. The most critical innate antiviral mechanism is the production of
Interferon, which is secreted and act in an autocrine and paracrine fashion. The
recognition of interferon leads to the expression of hundreds of interferon-stimulated
genes (ISGs). This primarily leads to either production of antiviral proteins like protein
kinase R (PKR) that inhibit viral protein synthesis or the production of 2', 5'-oligoadenylate
synthetase family that degrades viral RNA. The adaptive immune responses are
characterized by two main components namely humoral immunity generating specific
antibodies and cell-mediated effectors against a pathogen. The primary function of the
acquired immune system is the specific recognition of non-self-antigens presented in
context with Major histocompatibility complex (MHC) molecules, generation of tailored
responses to eliminate pathogen or pathogen-infected cells, and the development of
immunologic memory. Together, the innate and adaptive immune responses hinder viral
replication and propagation.

1.1

Pathogen pattern recognition receptors
The host innate immune response sets within a few hours of viral infection. The

degree and magnitude of such response decide the outcome of infection, containment or
dissemination. Host cytoplasmic pattern recognition receptors (PRR) initiate the antiviral
immune response that recognizes pathogen-associated molecular patterns (PAMPs) of
viral nucleic acid. The primary PRRs families are Toll-like receptors (TLR), retinoic acidinducible gene-I (RIG-I) like receptors (RLR) and Nucleotide-binding and oligomerization
domain (NOD)-like receptors (NLR) (Figure 1). The binding of PAMPs to PRRs activates
downstream signals to stimulate the transcription of a broad spectrum of genes to
produce cytokines and chemokines (Wilkins and Gale, 2010) . Production and secretion of
interferon including type-I interferon (IFN-I)/ IFN-αβ or type II interferon (IFN-II), or type
III interferon (IFN-III)/ IFN-λ is a central event. The IFN pathway signaling is central to the
generation of an antiviral state through ISGs in virus-infected and non-infected cells (S.-Y.
Liu et al., 2011) . IFNs act as the first line of cell-intrinsic defense against viral infection
and play a crucial role in initiating adaptive immune responses.
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Figure 1: TLR, RLR, and NLR signaling pathways.
Three known innate immune sensors; TLRs, RLRs, and NLRs recognize harmful signals such
as PAMPs, DAMPs, non-self nucleic acid, change in ionic or redox state at the cell surface,
in the endosome or the cytoplasm. The recognition by TLRs and RLRs activate secondary
messengers, which ultimately transduce the signal for activation and nuclear
translocation of transcription factors such as IRFs, NFκB, and AP-1 that
stimulate expression of cytokines like IFN-α/β, TNF and pro-IL-lβ. The NLRs further
promotes the assembly of the caspase-1 inflammasome and subsequent maturation of IL1β from pro-IL-1β (As adapted from Theofilopoulos et al. 2010).
Abbreviations: Danger-associated molecular pattern (DAMP), interleukin-1 (IL-1),
interferon regulatory factor (IRF3), nuclear factor kappa-light-chain-enhancer of activated
B cells (NFκB), Activator protein 1 (AP-1)
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1.1.1 The RLR pathway

The two RLRs, RIG-I/ DExD/H-Box Helicase 58 (DDX58) and melanoma
differentiation-associated 5 (MDA5) / interferon induced with helicase C domain 1 (IFIH1),
sense double-stranded viral RNA (Onoguchi et al., 2011) . Engagement of viral RNA leads
to a conformational change in RLR. In the open conformation, the amino-terminal
caspase recruitment domain (CARD) is available to interact with mitochondrial antiviral
signaling protein, mitochondrial antiviral signaling protein (MAVS) (Seth et al., 2005) .
Activated MAVS undergoes topological change to expose its TNF receptor-associated
factor 3 (TRAF) -interacting motif (TIM) domain for binding to TRAF3 and TRAF6 (Paz et
al., 2011) . This leads to activation of canonical I-kappa-B kinase (IKKs) and related kinases
like tumor necrosis factor receptor-associated factor (TRAF)-family member-associated
NF-B activator (TANK)-binding kinase 1 (TBK1) (Pichlmair et al., 2006) . MAVS is also
involved in assembling NF-kappa B Essential Modulator (NEMO) and TBK1 complex on the
mitochondrial surface. MAVS is then degraded by proteasomal machinery to release this
complex into the cytosol. Further, TBK1 phosphorylates interferon regulatory factor (IRF3)
(Castanier et al., 2012) . The phosphorylated IRF3 dimerizes and translocates to the
nucleus to bind to the ISRE promoter to trigger IFN production (Z. Wang et al., 2016) .
Peroxisome also provides a platform for co-localization of activated MAVS. It induces IFNindependent antiviral response characterized by rapid and short-term protection (Dixit et
al., 2010) .
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1.1.1.1 Regulation of the RLR signaling:

Stimulation of both innate and adaptive immune pathways is crucial to host
defense against infection. At the same time, these pathways are subjected to stringent
regulation by cellular factors to maintain an appropriate degree of immune responses and
to prevent cellular damage. All signaling pathways and activated proteins must be
regulated, and the RLR pathway is no exception to this. Stringent regulatory mechanisms
are needed to prevent any deleterious effect on the host.

1.1.1.2 Regulation of immune pathways by post-translation modifications

Post-translation modifications (PTM) is another mechanism by which various
molecules involved in immune signaling are modified and regulated for its activation or
destruction. PTMs increase the functional diversity of the proteome by the covalent
addition of functional groups or proteins, proteolytic cleavage of regulatory
subunits, or degradation of complete proteins. These modifications include
phosphorylation,

glycosylation,

ubiquitination,

nitrosylation,

methylation,

acetylation, lipidation and proteolysis, and influence almost all aspects of normal
cell biology and pathogenesis.
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1.1.1.2.1 Ubiquitination

Ubiquitination is one of the universal posttranslational protein modifications
occurring in the cell. Ubiquitin, an evolutionarily highly conserved 76 amino acid
polypeptide, is covalently attached to lysine residues of target proteins through a highly
organized and hierarchical group of enzymes. As there are seven lysine residues on
ubiquitin, it is possible that during ubiquitination, new ubiquitin molecules added to one
of the seven lysine residues of the previously conjugated ubiquitin. This process, called
polyubiquitination, is a standard cellular signal. Depending on the usage of the lysine
residues on ubiquitin, various linkage-specific ubiquitinations could happen; which
include K6, K11, K27, K29, K33, K48, K63, and M1. K48 and K63 linkage-specific
ubiquitinations are the most effective forms of polyubiquitination; In contrast to the
proteolytic role of the K48-specific linkage, the K63-specific linkage has been
demonstrated to regulate a variety of nonproteolytic cellular functions, including
deoxyribonucleic acid (DNA) damage repair, stress responses, and inflammatory
pathways (Figure 2)
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Figure 2: Types of ubiquitination and their role in cellular processes.
Mono-ubiquitination of the target protein is involved in protein interaction and
localization. Poly-ubiquitination of K-48 and K-11 was found to be required for
proteasomal degradation. Ubiquitination of K-63 chain plays a role in NF-κB activation,
DNA repair, and lysosomal targeting. Linear chain M1 poly-ubiquitination was found to
activate NF-κB signaling. The function of various other types ubiquitination including K-6,
K-29, K-33, K-27, heterogenous chain, and branched chain is not known As adapted
from(C. W. Park and Ryu, 2014) .
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1.1.1.3 Regulation of RLR signaling by host cellular proteins

The levels of RIG-I are subjected to transcriptional and post-transcriptional
regulations, which maintain its appropriate response. Post-translational modifications
activate or deactivate the protein function, which ultimately decides the fate of the
signaling pathway. An E3 ligase including tripartite motif-containing (TRIM)-25 binds to
the CARD domain of RIG-I, resulting in the conjugation of K-63 ubiquitin chain to the
lysine 172 of the CARD domain. Ubiquitination of RIG-I is critical for its activation and
binding to MAVS that ultimately activate IFN production (Matsumiya and Stafforini, 2010)
. TRIM25 B30.2 domain interacts with both CARD1 and CARD2 domains of RIG-I to open
the N terminal α helix (D'Cruz et al., 2018) .
MAVS is a central mediator of the RLR pathway and subjected to the regulation by
host factors and is also the target of viral proteins (F. Liu and Gu, 2011) . The host protein
NLR family member X1 (NLRX1) co-exists with MAVS on the outer mitochondrial
membrane. It was found to be a potent inhibitor of MAVS-mediated IFNβ promoter
activity (Moore et al., 2008) . Another protein, Poly C binding protein2 (PCBP-2) is induced
after viral infection. It recruits E3 ligase, atrophin-interacting protein 4 (AIP4), which
polyubiquitinates MAVS leading to proteasomal degradation (You et al., 2009) . Thus,
NLRX1 and PCBP2 are involved in the negative regulation of MAVS-mediated signaling.
Another host protein HSCARG was found to regulate IFNβ production negatively
(Figure 3). Following the viral infection, HSCARG interacts with TRAF3 and cooperates
with ovarian tumor (OTU) deubiquitinase Ubiquitin Aldehyde Binding (OTUB1) to remove
8

Lys63-linked polyubiquitin chain from TRAF3. This further decreases the recruitment of
IKKε and results in decreased phosphorylation of IKKε and IRF3, and finally reduces the
production of IFN-β (Peng et al., 2014) . Some host proteins like ring finger protein 5
(RNF5), Itchy ubiquitin E3 protein ligase (ITCH), myeloid differentiation primary response
88 (MyD88), and interleukin1 receptor-associated kinase (IRAK) participates in the
regulation of RIG-I and TLR pathway (Heaton et al., 2016) .

1.1.1.4 Regulation by TRIM proteins

Upon recognition of RNA viruses, RIG-I induces the synthesis of inflammatory
cytokines and type I IFNs. Briefly, RIG-I recruits the adapter MAVS and activates NF-κB
(p50/RelA heterodimer) and IRF3 via IKKα/IKKβ/NEMO and TBK1/IKKi, respectively. The
transcription factor is translocated to the nucleus and promote IFN transcription,
translation, and secretion. The secreted IFNs activate the STAT1/STAT2/IRF9 complex via
JAK or tyrosine kinase (TYK) to induce ISGs, including TRIM proteins.
More than 60 TRIM proteins are known in human and mice. IFN-I/ IFN-II induces
several TRIM proteins that are involved in the tight regulation of antiviral immune
pathways. Many TRIM proteins like TRIM 5, 8, 11, 21, 25, 32, 63 have E3 ubiquitin ligase
activity (Keiko Ozato et al., 2008a) . Several cellular target proteins and their positive or
negative regulation by TRIM have been identified (Figure 4). TRIM25 induces the
ubiquitination of RIG-I to promote downstream signaling. TRIM23 enhances NEMO
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function by promoting ubiquitination and TRIM27 interferes with IKKα/IKKβ and
TBK1/IKKi activation. TRIM21 is involved in the inhibition of IKKβ and IRF7 and positive or
negative regulation of IRF3 and IRF8. TRIM56 enhances STING function during DNA sensor
signaling pathways for the induction of type I IFNs (Kawai and Akira, 2011) . Collectively,
due to the diversity of TRIM proteins, they are capable of either stimulation or inhibition
of a signaling pathway that is involved in recognition of PRRs.
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Figure 3: A model of TRAF3-dependent regulation of RLR signaling pathway by HSCARG.
Following the viral infection, HSCARG interacts with TRAF3 and OTUB1 to decreases the
recruitment of IKKε and results in decreased phosphorylation of IKKε and IRF3, and finally
reduces the production of IFN-β As adapted from (Peng et al., 2014) .
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Figure 4: Regulation of RIG-I and DNA sensor signaling by TRIM proteins.
TRIM25, TRIM23, and TRIM56 positively regulate RIG-I, NEMO, and STING, respectively.
TRIM27 negatively regulates IKK complex or TBK1 activity. TRIM21 shown to inhibit
NEMO-IKK complex and IRF7 activity and able to regulate both positively or negatively
IRF8 and IRF3 activity As adapted from (Kawai and Akira, 2011)
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1.2

Interferon response

As a result of viral recognition and downstream signaling, fibroblast and
monocytes secrete IFN-I. IFN-Is bind the cell surface receptor IFN-α/β receptor (IFNAR1/2)
heterodimer, which then recruits, two JAK molecules. JAK phosphorylates IFNAR and
STAT, which then dimerize and enter the nucleus and transcribe ISGs. Several ISGs directly
inhibit virus infection by targeting the early or late stage of the viral life cycle in the host.
This fast and amplified response combats viral infection (Schneider et al., 2014) .

1.2.1 Interferon types and receptors

Type I IFNs comprise the most significant IFN class, and all human cells are capable
of IFN-I production(Siegal et al., 1999) . This class involves IFN-α, IFN-β, IFN-ε, IFN-κ, and
IFN-ω, which are all grouped on chromosome 9. IFN-I is recognized by the heterodimeric
receptor complex containing IFNAR1 and IFNAR2 subunits (Figure 5). The different types
of IFN-I show differential tissue expression level and binding affinity for the IFNAR1/2
receptor complex (Pestka et al., 2004) .

There is only one type II IFN, IFN-γ. It is a homodimeric protein recognized by the
IFN-γ receptor complex (IFNGR). Two IFNGR1 subunits initiate binding to IFN-γ followed
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by the recruitment of two auxiliary IFNGR2 subunits and results in receptor enactment
(Walter et al., 1995) . IFN-γ production is to a great extent confined to immune cells.
However, the IFNGR1/2 receptors are broadly distributed, and almost all cell types are
responsive to IFN-γ (Valente et al., 1992) . Two primary functions of IFN-II are immune
regulation and connecting innate immune responses to adaptive immunity. Broadly, IFN-II
is involved in up-regulation of pathogen recognition, antigen processing and presentation,
antiviral state, inhibition of cellular proliferation and effects on apoptosis, activation of
microbicidal effector functions, immunomodulation, and leukocyte trafficking (Schroder
et al., 2004) .
The more recently discovered IFN-III subfamily is comprised of IFNL1/ IFNλ1/
interleukin (IL)-29, IFNL2/ IFNλ2/ IL-28A, IFNL3/ IFNλ3/ IL-28B. All three IFN-λs signal
through the same heterodimer receptor complex composed of IFNLR1 and interleukin -10
receptor 2 (IL-10R2) (Sheppard et al., 2003) . IFN-λs may interfere with virus infection by
various mechanisms including direct antiviral effect, or as a modulator of IFN-α-induced
signaling via the suppressor of cytokine signaling 1 (SOCS) and the ubiquitin-specific
peptidase 18 (USP18) inhibitory feedback loops (Syedbasha and Egli, 2017) . IFN-III
showed potent antiviral Encephalomyocarditis virus (EMCV) activity in vitro but was
unable to reduced infection in the murine model when treated singularly. On the other
hand, IFN-III treatment prevents the disease pathogenesis by blocking herpes simplex
virus-2 (HSV-2) replication in the vaginal mucosa (Ank et al., 2006) . IL28B contributes to
Hepatitis C virus (HCV) resistance and is known to be upregulated by interferon and by
RNA virus infection (Suppiah et al., 2009) .
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Figure 5: IFN-I, IFN-II, and IFN-III signaling.
IFN-I, IFN-II, and IFN-III bind to distinct receptors namely IFNAR1- IFNAR2 dimer, IFNGR1IFNGR2 tetramer, and IFNLR1-IL10R2 dimer, respectively. Association of IFN with the
receptor complex activates TYK2 and JAK1 kinases, which phosphorylate and dimerize
STAT1 and STAT2. Phosphorylated STAT1-STAT2 dimer in association with IRF9 generates
the ISGF3 complex. The IFN and receptor binding could also generate phosphorylated
STAT1 dimer as a transcription factor. The transcription factors, ISGF3 or STAT1 dimer,
translocate to the nucleus and bind to ISRE to activate transcription of several ISGs. As
adapted from (https://www.creative-diagnostics.com/blog/index.php/interferons-andinterferon-receptors/)
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Figure 6: Antiviral innate immune signaling involves three following significant events.
First, recognition of viral DNA/ RNA by PRRs to activate IFN production. Second, the
association of secreted interferon with IFNR to express hundreds of ISGs. Third, the action
of ISGs as antiviral effectors or regulate these two pathways positively or negatively As
adapted from (Schneider et al., 2014)
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1.2.2 Interferon response- JAK-STAT pathway

Association of IFN with the receptor complex activate JAK-STAT signaling pathway
(Figure 6). Briefly, IFNRs specifically recognize IFN and dimerize two receptor subunits,
which activates TYK2 and JAK1 kinases, which phosphorylate and dimerize STAT1 and
STAT2. Phosphorylated STAT1-STAT2 dimer in association with IRF9 generates the ISGF3
complex. The IFN and receptor binding could also generate phosphorylated STAT1 dimer
as a transcription factor. The transcription factors, ISGF3 or STAT1 dimer, translocate to
the nucleus and bind to ISRE to activate transcription of several ISGs.

1.2.2.1 Janus Kinases (JAKs)

The known JAKs include JAK1, JAK2, JAK3, and TYK2 (Kawamura et al., 1994)
(Stark et al., 1998) . They comprise the catalytic kinase domain and regulatory pseudokinase domain (Ke Shuai and Liu, 2003) .

1.2.2.2 STAT

There are seven known mammalian STATS, STAT1, STAT2, STAT3, STAT4, STAT5A,
STAT5B, and STAT6. They have homologous regions of SRC homology 2 (SH2) domain,
DNA-binding domain, and a transactivation domain. The amino-terminal region of
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STATs is involved in regulating STAT activity, such as the formation of STAT tetramers
(Xu et al., 1996) and tyrosine dephosphorylation (K. Shuai et al., 1996) .

1.2.2.3 Interferon-stimulated genes: ISG

ISGs are involved in various effector function including directly targeting
molecules required during the pathogen life cycle, maintaining cellular homeostasis by
regulating antiviral state, pro-apoptotic proteins leading to cell death (Schneider et al.,
2014) . ISGs are capable of enhancing pathogen recognition properties as well as
regulating signaling through the JAK-STAT pathway. Some PRRs and IRFs expression is
amplified by IFN, leading to enhanced pathogen recognition. A subset of ISGs is capable of
IFN-independent activation to counteract pathogen-mediated innate immune evasion
strategies (Iwasaki, 2012) .
A recent study aimed to decipher molecular mechanisms of ISG network identified
104 ISGs interactions and 1401 cellular partners. Various ISGs interact with some shared
partners suggesting their central role in ISG mediated antiviral immune response. While
few others attribute to specific interactome, suggesting a discreet role in particular viral
infection (Hubel et al., 2019) .
Interferon-induced transmembrane protein-1 (IFITM1), IFITM2, and IFITM3
coordinate to induce antiviral activity in the interferon-stimulated cell. Endosomal IFITM3
combines with entering viral particle and inhibits viral fusion with lysosomal membrane
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and thus release of the viral genome to the cytoplasm for replication. IFITM3 binding to
the virus is specific and require s-palmitoylation (Ritz et al., 2011) . Although Spalmitoylation enhances IFITM3 membrane affinity and antiviral activity, ubiquitination
decreases its localization with endolysosomes and antiviral activity in influenza infection
(Yount et al., 2012) .
Oligoadenylate synthetase (OAS) detects cytosolic PAMPs leading to the synthesis
of 2′-5′-oligoadenylates, which then act as intracellular second messengers to activate
latent RNaseL. Activated RNase L degrades viral RNA, which can be sensed by RLRs,
ultimately amplifying IFN response (Chakrabarti et al., 2011) .
They are two Myxovirus resistance (Mx) proteins, Mx1/ MxA, and Mx2/ MxB,
which are related to dynamin-like large guanosine triphosphatases (GTPases) family of
protein. Mx proteins are found to potently block viral entry by trapping incoming viral
nucleotides and preventing its cellular movement. Mx1 contains a central stalk domain
and a GTPase effector domain, which are both essential for self-oligomerization and
formation of ring-like structures that bind to and impose conformational changes on the
target protein (Klockow et al., 2002) . Mx2 potently inhibits human immunodeficiency
virus 1 (HIV-1) and HIV-2 entry (Kane et al., 2013) . It keeps the reverse-transcribed
genome from reaching its nuclear destination, thereby ultimately inhibiting chromosomal
integration, which is an essential event of the HIV-1 replication cycle (Z. Liu et al., 2013) .
IFN stimulation induces several TRIM family of proteins. TRIMs are composed of
60 members and mainly function as an E3 ubiquitin ligase (K. Ozato et al., 2008b) . One of
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the most studied TRIM as an ISG is TRIM5α, a potent inhibitor of HIV-1 entry (Stremlau et
al., 2004) . TRIM5α binds to HIV-1 capsid, uncoating and exposing the viral nucleoprotein
complex (Campbell et al., 2008) . Another protein TRIM22 inhibits expression of the HIV-1
long terminal repeats (Tissot and Mechti, 1995) . It also inhibits trafficking of the HIV-1
Gag protein to the host cell plasma membrane, resulting in reduced viral production (Barr
et al., 2008) . TRIM22 has also been shown to inhibit multiple viruses by various
mechanisms. It inhibits transcription from the core promoter of hepatitis B virus (HBV),
blocks EMCV replication by promoting ubiquitination of the viral 3C protease, and targets
influenza A virus nucleoprotein for proteasomal degradation (Schneider et al., 2014) .
Activation of dsRNA dependent PKR via IFN stimulation leads to a significant
reduction in host mRNA production/ translation. In contrast, PKR is found to be crucial for
the integrity of newly synthesized IFN mRNA to generate an optimal host antiviral
immune response. Also, PKR is involved in the degradation of the inhibitor of κB (IκB),
resulting in activation of the NF-κB signaling pathway (Munir and Berg, 2013) .

1.2.2.4 IFN desensitization

Interferon stimulation induces transcription of two genes, IFN-IND1 and IFN-IND2
within 30 minutes to 2 hours. Shortly after that cells undergo an IFN- desensitized state. It
allows cells to recover from the IFN signaling expenditure (Larner et al., 1986) . Diverse

20

mechanisms achieve this negative regulation; some are cell intrinsic, while others are ISG
mediated.
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1.2.2.5 Regulation of interferon response by Post-translation modifications

PTM activates/ deactivates proteins rapidly leading to a quick response in signal
transduction. PTM regulating JAKs and STATs functions includes phosphorylation,
methylation, ubiquitination, and ISGylation.
Tyrosine phosphorylation of JAK2 is required for its efficient ubiquitination.
JAK2 is ubiquitinated and rapidly degraded, which can be enhanced by IL-3 and IFN-γ.
The SOCS box of SOCS1, which interacts with elongins B and C, is required for the
ubiquitination of JAK2. So, the stability of JAK2 seems to be regulated by a SOCS1mediated ubiquitin-proteasome pathway (Ke Shuai and Liu, 2003) .
In a process known as ISGylation, a small IFN-induced gene 15 (ISG15) that is
ubiquitin-like protein is covalently attached to target proteins through a series of steps
that mirror the ubiquitination pathway. ISG15 ISGylates JAK1 and STAT1 to regulate
their function (Malakhova et al., 2003) . The removal of ISG15 conjugates (de-ISGylation)
is performed by the isopeptidase activity of an ISG, USP18. (Malakhov et al., 2002) USP18
is a chief player in maintaining long-lasting desensitization of IFN-I signaling by ISGylationdependent and independent manner. In an ISGylation independent mechanism, USP18
binds to the intracellular domain of IFNAR2, which prevents the binding of
JAK1 (Malakhova et al., 2006) .
The intracellular conserved domain of IFN receptor, Serine 532, is phosphorylated
and subsequently ubiquitinated by Skp, Cullin, F-box protein (SCF) E3 ubiquitin ligases.

22

However, the exact mechanism and outcome of ubiquitination are not clearly
understood.
The tyrosine phosphorylation of JAKs and STATs catalyzes their activation.
Independently, serine phosphorylation is observed on STAT1, STAT3, STAT4, STAT5A,
and STAT5B (Levy and Darnell, 2002) . STAT1 is phosphorylated on Serine 727 by one of
several kinases including extracellular signal-regulated protein kinase (ERK), p38, JUN
N-terminal kinase (JNK), and protein kinase Cδ (PKCδ) (Decker and Kovarik, 2000) .
The arginine 31 methylation of STAT1 occurs constitutively, independently of
tyrosine or serine phosphorylation. It increases the DNA-binding activity of STAT1,
possibly due to inhibition of the interaction of PIAS1 with non-methylated STAT1
(Mowen et al., 2001) . The ubiquitin-proteasome pathway regulates polyubiquitination
of STAT1 (T. K. Kim and Maniatis, 1996) . It has been shown that STAT1 can be modified
by small ubiquitin-related modifier (SUMO)lyation on Lys703, which can be strongly
enhanced by PIAS proteins (Rogers et al., 2003) .

1.2.2.6 Regulation of IFN response by host proteins

Three primary JAK-STAT regulators include Suppressors of Cytokine Signaling
(SOCS), Protein Inhibitors of Activated STATs (PIAS) and Protein Tyrosine Phosphatases
(PTPs) (Figure 7).
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There are eight known SOCS proteins including CIS (cytokine-inducible SH2 domain
protein) and SOCS1–SOCS7 (Hilton, 1999) . SOCS proteins bind to phosphorylated
tyrosine residues, on either the JAKs or IFNRs, inhibiting JAK activity and STAT-binding.
The C terminus of SOCS recruits proteins involved in receptor ubiquitination and
proteasome degradation. SOCS proteins are induced early in the IFN response and play an
essential role in early IFN desensitization (Hong and Carmichael, 2013) . The SOCS box
can also bind to ubiquitin E3 ligase elongins B and C, suggesting that it targets signaling
proteins for proteasomal degradation (Zhang et al., 1999) .
The mammalian PIAS family consists of four members including PIAS1, PIAS3,
PIASX, and PIASY (K. Shuai, 2000) . PIAS has been shown to inhibit STAT-mediated gene
activation by three possible mechanisms. PIAS1 and PIAS3 prevent the binding of the
STAT dimers to DNA. While PIASX and PIASY might act as transcriptional co-repressors
of STAT by recruiting other co-repressor proteins such as histone deacetylase (HDAC).
PIAS proteins can regulate STAT1 by SUMO-lyation (Ke Shuai and Liu, 2003) .
PTPs regulate JAKs and exhibit specificity to negative regulation. Two SH2
domains-containing PTPase is SH-PTP1 and SH-PTP2 (Neel, 1993) . Another PTP, known
as CD45 can directly bind and dephosphorylate all JAKs (Irie-Sasaki et al., 2001) . Two
related PTPs, PTP1B and T cell protein tyrosine phosphatase (TCPTP), were shown to
dephosphorylate JAKs, mainly TYK2 and JAK2 and regulate their activity (Myers et al.,
2001) .
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Figure 7: Regulators of the JAK-STAT pathway.
suppressor of cytokine signaling (SOCS) proteins, protein tyrosine phosphatases
(PTPs), and Protein inhibitor of activated STAT (PIAS) As adapted from (Ke Shuai and Liu,
2003)
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1.3 UBXNs

The human genome encodes at least 13 ubiquitin-regulatory-X (UBX)-domaincontaining proteins (UBXN) (Alexandru et al., 2008) (Figure 8). Throughout the species,
individual UBXNs are well conserved. Based on their protein domain composition, the
human UBXNs are sub-classified into two main groups: the ubiquitin-associated (UBA)UBX proteins and UBX-only proteins. The UBA domain motifs are predicted to interact
with target proteins for nonredundant proteasomal degradation. The UBX domain of all
UBXNs might bind and influence the function of an ATPase associated with diverse
cellular activities (AAA)-ATPase, p97, which is also called as valosin-containing protein
(VCP) (Schuberth and Buchberger, 2008) . VCP is a multifunctional protein involved in
cellular processes like Endoplasmic-reticulum-associated protein degradation (ERAD),
autophagy, endosomal sorting, mitochondrial and cytoplasmic protein degradation
(Chapman et al., 2011) . The UBA-UBX domain proteins could bind to E3 ligase and
recognize K-11 and K-48 polyubiquitin chains, demonstrating their role in ubiquitindependent proteasomal degradation pathway. Association of UBXNs with the binding
partners like p97 and E3 ubiquitin ligases strongly suggests their role in the regulation of
global protein turnover and cellular signaling.
Ubiquitin-dependent proteasomal degradation is one of the most studied protein
degradation mechanisms. The role of VCP in ERAD is well established in this process.
Proteomic networking analysis of VCP and its UBX domain cofactors revealed that various
UBA-UBX domain-containing proteins form complexes with VCP and are also associated
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with E3 ubiquitin ligases. UBXNs have diverse roles, and the substrate-specific
degradation is carried out via specific UBXN-VCP complex. Interaction of VCP, nuclear
protein localization protein 4 (NPL4), and Ubiquitin Recognition Factor In ER-Associated
Degradation 1 (UFD1) with the substrate hypoxia-induced factor 1-α (HF-1α) and E3 ligase
requires UBXN7. In the native state, the UBA and UBX domains are bound to each other.
The UBX domain serves as a binding platform for VCP only when the UBA domain is
associated with a ubiquitinated substrate (Alexandru et al., 2008) .
The N-terminal domain of VCP binds multiple regulatory cofactors including the
UFD1/NPL4 heterodimer and UBXNs. The crystal structure of the UBXN3A/ FASassociated factor 1 (FAF1), UBX domain in complex with the VCP N domain, reveals that
the signature Phe-Pro-Arg motif known to be crucial for interactions of UBX domains with
VCP adopts a cis-proline configuration. Moreover, UBXN3A and UBXD7 only bind to VCPUFD1/NPL4, but not free VCP, thus demonstrating a hierarchy in VCP-cofactor
interactions (Hanzelmann et al., 2011) .
The

connections

among

VCP

and

the

PUB

[PNGase

(peptide

N-

glycosidase)/ubiquitin-associated] area of PNGase, the UBX space of p47, and the UBD
(ubiquitin D) space of NPL4 have been fundamentally described. The UBX and UBD are
auxiliary homologs that share comparable VCP-restricting modes. It is conceivable that
different proteins that contain a UBX/UBX-like space likewise associate with VCP using
comparable systems. Moreover, a few short VCP-collaborating themes, for example, VCPbinding motif (VBM), VCP-interacting motif (VIM) and SHP, have been recognized as of
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late and are additionally shared between VCP connectors, implying that proteins having
the equivalent VCP-restricting theme may likewise share standard VCP-restricting
components (Yeung et al., 2008) .
The overview of each UBXN including its aliases, size, domains and functions are
discussed further (Table 1).
1.3.1 UBXN1

Various UBXNs were found to be involved in decreased lentiviral and retroviral
production. UBXN1, UBXN9, and UBXN11 interfere with NF-κB pathway by binding to
Cullin 1 (CUL 1), which inhibits the inhibitor of kappa B (IκBα) degradation. UBXN1 was
found in being involved in murine embryonic cell development, cell adhesion, immune
response pathways (Hu et al., 2017) .
UBXN1 was shown to interfere with RNA virus-induced IFN-I response while
potentially increasing replication of viruses such as vesicular stomatitis virus (VSV),
Sendai, West Nile, and dengue virus. At the molecular level, UBXN1 targets MAVS and
blocks MAVS oligomerization, and disrupts the MAVS/TRAF3/TRAF6 signalosome,
ultimately affecting IFN production (P. Wang et al., 2013) . Similarly, UBXN1 was found to
regulate NF-κB signaling.

UBXN1, which contained both ubiquitin-associated and

ubiquitin regulatory X (UBX) domains acts as a negative regulator of TNFα-triggered NF-κB
activation. Over-expression of UBXN1 inhibited TNFα-triggered NF-κB activation, although
knockdown of UBXN1 had the opposite effect. UBX domain-containing proteins usually
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act as VCP cofactors. However, knockdown of VCP barely affected UBXN1-mediated NFκB inhibition. At the same time, we found that UBXN1 interacted with cellular inhibitors
of apoptosis proteins (cIAPs), E3 ubiquitin ligases of RIP1 in the TNFα receptor complex.
UBXN1 competitively bound to cIAP1, blocked cIAP1 recruitment to TNF receptor 1
(TNFR1), and sequentially inhibited receptor-interacting serine/threonine protein kinase 1
(RIPK1) polyubiquitination in response to TNFα. These findings demonstrate that UBXN1
is an essential negative regulator of the TNFα-triggered NF-κB signaling pathway by
mediating cIAP recruitment independent on VCP (Y. B. Wang et al., 2015) .
A recent study demonstrated that the induction of interferon is potentially
suppressed by Nipah virus V protein via UBXN1. Briefly, Nipah virus V protein interacts
with the UBX domain of UBXN1 via its proximal zinc-finger motif in the C-terminal
domain. Also, the level of UBXN1 is increased in Nipah infection, by suppressing its
proteolysis. Additionally, Nipah virus V protein suppressed RIG-I and MDA5-dependent
interferon signaling by stabilizing UBXN1 and increasing the interaction between MAVS
and UBXN1 (Uchida et al., 2018) .
UBXN1 was shown to negatively modulate ERAD. This requires the ability of
UBXN1 to bind both polyubiquitin and VCP. Moreover, the binding of UBXN1 with VCP is
positively regulated by polyubiquitin binding of the UBX protein. It was found that UBXN1
also negatively regulate the VCP-dependent processing required for degradation of a
cytosolic, non-ERAD, substrate. Additionally, UBXN1 protect polyubiquitin from the
activity of deubiquitinases, such as ataxin-3, that are necessary for efficient ERAD. Thus,
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UBXN1 inhibits protein degradation mediated by VCP complexes by protecting
polyubiquitin chains from deubiquitination (LaLonde and Bretscher, 2011) .
Another recent study demonstrates that UBXN1 is negatively regulated by
epidermal growth factor receptor mutation vIII (EGFRvIII), which play a significant role in
glioblastoma cancer. The upregulation of H3K27me3 mediates the down-regulation of
UBXN1 in the presence of EGFRvIII. EGFRwt/vIII activate NF-κB by suppressing UBXN1
expression (Huang et al., 2017) . Another cancer study revealed that UBXN1 polypeptide
recognizes auto-ubiquitinated breast cancer type 1 susceptibility protein (BRCA1) via the
UBA domain. The recognition is made in a bipartite interaction in which the UBA domain
of UBXN1 binds K6-linked polyubiquitin chains conjugated to BRCA1 and the C-terminal
domain of UBXN1 bind the BRCA1/ BRCA1 Associated RING Domain 1 (BARD1)
heterodimer in a ubiquitin-independent fashion. The E3 ligase activity of BRCA1/BARD1 is
drastically reduced in the presence of UBXN1. Thus, UBXN1 regulates the enzymatic
function of ubiquitinated BRCA1 (Wu-Baer et al., 2010) .

1.3.2 UBXN2A

UBXN2A binds to Mortalin (mot2) and prevents p53-mot2 complex formation.
Mot 2 inactivates the tumor silencer p53's transcriptional and apoptotic function by
cytoplasmic sequestration of p53 in select malignancies. Interrupted p53-mot 2
interactions can control the development of disease cells in colon cancer. The interaction
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also discharges p53 from cytosolic sequestration, safeguarding the tumor silencer
elements of p53. Thus UBXN2A acts as a home defense response protein, which can
reconstitute inactive p53-dependent apoptotic pathways. Inhibition of mot2-p53
interaction by UBXN2A is an attractive therapeutic target in mot2-elevated colon cancer
(Sane et al., 2014) .
UBXN2A also binds to alpha3, alpha4 subunits of neuronal nicotinic acetylcholine
receptors (nAChRs). This binding affects alpha3 ubiquitination and proteasomal
degradation. Thus, UBXN2A affects the stability and cell surface number of these
receptors (Rezvani et al., 2009) .

1.3.3 UBXN2B

VCP complexes with UBXN2B in the cytosol and localizes to the Golgi and
Endoplasmic reticulum (ER). VCP-UBXN2B complex showed membrane fusion activity
(Uchiyama et al., 2006) . Another study showed that phosphorylation of UBXN2B on
Serine-56 and Threonine-59 by Cdc2 at mitosis, and this phosphorylated UBXN2B does
not bind to Golgi membranes.
UBXN2B phosphorylation

inhibits

the VCP/UBXN2B pathway.

These

results

demonstrate that UBXN2B phosphorylation on Serine-56 and Threonine-59 is essential for
Golgi disassembly at mitosis (Kaneko et al., 2010) .
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UBXN2B regulates the orientation of the spindle, which is a crucial step in cell
division process and determines tissue morphogenesis and development of an organism.
Briefly, spindle orientation is regulated via Gαi-LGN- nuclear mitotic apparatus protein
(NuMA) complex. UBXN2B inhibits cortical NuMA levels via the protein phosphatase 1
(PP1) and its regulatory subunit Repo-Man. In metaphase, UBXN2B negatively regulates
the accumulation of NuMA, resulting in lower cortical NuMA levels and correct spindle
orientation (B. H. Lee et al., 2018) .
PP1 exhibits different functional reaction with many substrates by the assembly of
alternative PP1 holoenzymes. Newly formed holoenzyme needs to be disassembled by
the VCP AAA-ATPase to promote exchange for the substrate. UBXN2B acts as an adaptor
in this process. The UBXN2B shp1, eyc, and p47 (SEP) domain interact with inhibitor-3 (I3)
without the need for ubiquitination. Thus, VCP-UBXN2B complex function in a ubiquitinindependent manner in PPI biogenesis (Weith et al., 2018) .
In a recent study, VCP inhibitor analogs were evaluated for their ability to inhibit
the ATPase activity against VCP, VCP-UBXN2B or VCP- Npl4-Ufd1 heterodimer (NU). The
protein sequence of UBXN2B is 50 % identical to that of p47. However, unlike p47,
UBXN2B does not significantly change the potencies of most of the tested analogs,
suggesting complex -specific VCP inhibitors need to be developed (Gui et al., 2016) .

1.3.4 UBXN3A
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UBXN3A associates with Fas-associated death domain protein (FADD) and caspase
8. The death effector domains (DEDs) of caspase-8 and FADD interacts with the amino
acid 181-381 region of UBXN3A. Its over-expression in Jurkat cells causes apoptotic
death. It is suggested that UBXN3B is a member of multiple Fas-death-inducing signaling
complex (Fas-DISC), acting upstream to caspase 8 (Ryu et al., 2003) . Also, UBXN3B can
drive breast cancer metastasis. UBXN3A destabilizes transforming growth factor β
receptor II (TGF-βRII) on the cell surface by recruiting the VCP/E3 ligase complex. AKT
phosphorylates UBXN3B at ser582, which abrogates UBXN3A activity and increases cell
surface receptor availability. It leads to heightened TGF-β response and epithelial-tomesenchymal transition (EMT) and metastasis (Xie et al., 2017) .
UBXN3A positively regulates RNA virus-induced antiviral responses. Briefly, it
competitively binds with NLRX1, which liberates MAVS from NLRX1-inhibited state. The
free MAVS can bind to RIG-I and activate downstream signaling (J. H. Kim et al., 2017) .
UBXN3A can also regulate MAVS activity by a different mechanism. TRIM31 is an E3 ligase
that catalyzes lysine 63-linked poly-ubiquitination of MAVS. UBXN3A can antagonize the
poly-ubiquitination and aggregation of MAVS by competing with TRIM31. Also, viral
infection triggers the kinase IKKɛ directly which phosphorylates serine 556 of UBXN3A and
triggers UBXN3A de-aggregation. Moreover, Ser556 phosphorylation promotes UBXN3A
lysosomal degradation, consequently relieving UBXN3A-dependent suppression of MAVS
(Dai et al., 2018) .
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The UBXN3A N-terminal UBA domain recognizes Lys(48)-ubiquitin linkage to
recruit polyubiquitinated proteins and its C-terminal UBX domain interacts with VCP. VCP
association to the C-terminal UBX domain regulates ubiquitin binding to the N-terminal
UBA domain. The VCP-Npl4-Ufd1 complex is known as the machinery required for
endoplasmic reticulum-associated degradation. UBXN3A binds to VCP-Npl4-Ufd1 complex
via its UBX domain and polyubiquitinated proteins via its UBA domain to promote ERAD
(J. J. Lee et al., 2013) .
UBXN3A is involved in negative regulation of NF-kappaB activation. UBXN3A binds
to NF-kappaB p65 via its death effector domain (DED)-interacting domain (amino acids
181-381), where DEDs of the Fas-associated death domain protein and caspase-8 interact
(M. Y. Park et al., 2004) .

1.3.5 UBXN3B

UBXN3B plays a role in the regulation of lipid metabolism. UBXN3B is capable of
sensing unsaturated fatty acids (FAs). This exposure alters UBXN3B structure. It ultimately
results in the inhibition of the synthesis of triglyceride (TGs) from diacylglycerols (DAGs)
(J. N. Lee et al., 2010) . Another study showed that trafficking of UBXN3B to lipid droplets
(LD) is restricted when it associates with ER-resident pseudo-protease UBA domain
containing 2 (UBAC2). Also, LD size is increased when VCP is recruited to LD via UBXN3B
association. This has resulted from an inhibition of adipose triglyceride lipase (ATGL)
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activity and dissociation of co-activator comparative gene identification (CGI-58)
(Olzmann et al., 2013) .
Hepatocyte-specific UBXN3B knockout mice on a high-fat diet showed significantly
lower serum triglyceride and secreted very low-density lipoprotein (VLDL) as compared to
wild type mice. Lipidated apolipoprotein B (ApoB) was accumulated in lipid droplet of
UBXN3B knockout mice hepatocytes. The accumulation could ultimately result in
periportal macrovascular steatosis (Imai et al., 2015) . UBXN3B was shown to target HMGCoA reductase (HMGCR) to its proteasomal degradation. It affects rate-limiting enzymatic
catalysis of the mevalonate pathway. Thus, UBXN3B is also capable of regulating de novo
sterol biosynthesis to control cholesterol synthesis (Loregger et al., 2017) .
Our recent study demonstrated that UBXN3B positively regulates STING signaling.
STING was first identified as a DNA sensor and recently shown to be involved in anti-viral
responses against RNA viruses also. Ubxn3b knockout mice, like Sting knockout mice, are
highly susceptible to lethal herpes simplex virus 1 (HSV-1) and VSV infection, which is
correlated with deficient immune responses. Functional studies demonstrate that
UBXN3B interacts with both STING and activate STING signaling via ubiquitination,
dimerization, trafficking. Thus, UBXN3B is involved in the positive regulation of STING
signaling (Yang et al., 2018) .

1.3.6 UBXN4
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UBXN4/UBXD2/erasin is an ER and nuclear envelope integral membrane protein
with both its N- and C-termini facing the cytoplasm or nucleoplasm. A single 21-aminoacid sequence located near the C-terminus is necessary and sufficient for localization of
UBXN4 to the ER. UBXN4 protein expression increases during stress. It binds VCP via its
UBX domain and triggers ERAD substrate CD3delta. Also, UBXN4 was found to
accumulates preferentially in neurons undergoing neurofibrillary degeneration in
Alzheimer's disease (Liang et al., 2006) . Knockdown of UBXN4, which serves a binding
platform for VCP and ubiquitin in human cells slowed the degradation of two classical
ERAD substrates. In Caenorhabditis elegans, ubiquitin and UBXN4 are ER stress-response
genes that are regulated by the ire-1 branch of the unfolded protein response pathway.
Loss of ubiquitin or UBXN4 activates ER stress, increases the accumulation of
polyubiquitinated proteins, and shortens the lifespan of worms. These results
demonstrate a role for this complex in ERAD and the regulation of ER stress (Lim et al.,
2009) .

1.3.7 UBXN6

UBXN6 is one of the essential cofactors of VCP involved in the endolysosomal
localization leading to autophagy. Upon endosome and lysosome rupture, VCP is
recruited along with cofactors UBXN6, phospholipase A-2-activating protein (PLAA), and
deubiquitinating enzyme YOD1. This endo-lysosomal response complex acts downstream
of K-63 ubiquitination and p62 recruitment. It stimulates autophagy by selectively
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removing K-48 ubiquitinated proteins from damaged lysosomal repertoire (Papadopoulos
et al., 2017) .
VCP in the association of several co-factors involved in the cellular processes that
maintain homeostasis. Mutations at the interface between the N-terminus and the first
of two ATPase areas (D1 and D2) in VCP deregulate the ATPase action and cause a
multisystem degenerative disorder, inclusion body myopathy in Paget disease of bone
and frontotemporal dementia/amyotrophic lateral sclerosis. These mutations found to
prominently weaken the VCP- UBXN6 interaction during caveolin-1 (CAV-1)
endolysosomal sorting. The N-terminus of UBXN6 is critical and can be classified as
intrinsically disordered. The N-terminal helices 1 and 2 of UBXN6 bind with VCP motifs.
Additionally, two distant epitopes on the VCP N-domain that include disease-associated
residues and additional interaction between UBXN6-N terminus and the D1D2 barrel of
VCP were identified. Functionally, binding of UBXN6 to VCP led to a reduction of ATPase
activity and partial protection from proteolysis. Together, this study indicates that UBXN1
N terminus intercalates into the VCP and UBXN6-N terminal D1 interface, thereby
modulating interdomain communication of VCP domains and its activity (Trusch et al.,
2015) .
CAV1 is a plasma membrane-resident sorted to endosome and lysosome by VCPUBXN6 complex. Six lysine residues in the N-terminal region of CAV1 get ubiquitinated,
which then bind and recruit VCP-UBXN6 complex to endosomes (Kirchner et al., 2013) .
VCP missense mutation leads to degenerative disease in humans, in which muscle-specific
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caveolin-3 accumulates in sarcoplasmic pools and specifically delocalizes from the
sarcolemma. The formation of CAV-VCP-UBXN6 complex is compromised by a diseaseassociated mutation, which leads to defective endosomal sorting of ubiquitylated CAV-1.
Thus UBXN6 activity was found to be affected by VCP mutation (Ritz et al., 2011) .
VCP, in association with the Ufd1-Npl4 heterodimer as an adaptor, plays an
essential role in ERAD. Several UBXNs recruit ubiquitinated substrates to VCP/Cdc48 by
binding both VCP/Cdc48 and other ERAD components such as ubiquitin ligases. UBXN6 is
involved in ERAD process. UBXN6 is a cytosolic protein that interacts with VCP and Derlin1. UBXN6 overexpression in cells causes selective dissociation of Ufd1 from VCP, resulting
in inhibition of mutant cystic fibrosis transmembrane conductance regulator (CFTR)
degradation by ERAD (Nagahama et al., 2009) .
The AAA ATPase complex is known as VCP in mammals, and the yeast homolog is
Cdc48. It is involved in various cellular pathways, including membrane fusion, protein
folding, protein degradation and activation of membrane-bound transcription factors.
This broad range of cellular involvement is executed via specific co-factors of VCP. UBXN6
is one of the co-factor of VCP. It localizes to the cytoplasm and nucleus and is highly
expressed in centrosomes. Phosphorylation of the penultimate tyrosine residue in VCP
completely abolishes UBXN6 interaction. Ternary complexes of UBXN6, p47 and VCP were
detected in vitro. Inhibition of UBXN6 expression by siRNA did not affect the degradation
of bulk protein or a model substrate of the ERAD pathway, indicating that UBXN6 directs
VCP activity to specialized functions in vivo (Madsen et al., 2008) .
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UBXN6 is a cofactor of VCP and possesses two binding domain namely UBX and
PUB. The PUB domain mediates robust binding to the C-terminus of VCP, while the UBX
domain does not contribute to VCP binding. Also, VCP possesses additional binding site in
UBXD1 that competes with the p47 cofactor for binding to the N domain of VCP. This
bipartite binding mode suggests that UBXN6 could be an effective regulator of VCP
cofactor interactions (Kern et al., 2009) .
UBXN6 shows a relationship with lectin mannose-binding 1, also called as ER-Golgi
intermediate compartment 53 kDa protein (ERGIC-53), a hexameric type I integral film
protein. The UBXD1-ERGIC-53 association requires the N-terminal ten deposits of UBXD1
and the C-terminal cytoplasmic 12 amino corrosive tail of ERGIC-53. Utilization of VCP and
E1 protein inhibitors show that development among UBXD1 and ERGIC-53 requires the
ATPase movement of VCP, however not ubiquitin change. Moreover, a UBXD1-Rab3GAP
affiliation requires the ERGIC-53 restricting space ofUBXN6. Confinement contemplates
showing that UBXD1 modules the sub-cell dealing of ERGIC-53, including elevating
development to the cell film. Thus, VCP-UBXD1 tweaks the dealing of ERGIC-53containing vesicles by controlling the connection of transport factors with the cytoplasmic
tail of ERGIC-53 (Haines et al., 2012) .
In Huntington disease mitochondrial outer membrane protein Myeloid cell
Leukemia sequence-1(MCL1) is degraded extensively via VCP. UBXN6 specifically
recognizes and bind to targets MCL1 and co-factors with VCP to extract MCL1 from
mitochondria. In the mutant Huntington gene, VCP-UBXN6 complex can significantly
degrade the MCL1 (Guo and Qi, 2017) .
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1.3.8 UBXN7

UBXN7 can participate in the degradation of misfolded or damaged proteins in the
VCP-mediated ubiquitin-proteasome system (UPS). UBXN7 binds to ubiquitinated
substrates via its UBA domain and interacts with VCP N-terminal domain through its UBX
domain to recruit VCP or the VCP core complex (VCP/NPL4/UFD1). The crystal structural
superpositions suggest that dimerization of UBXN7 via an intermolecular disulfide bond
could interfere with the formation of the VCP-UBXN7 complex. Interestingly, UBXN7 may
have a cooperative effect on VCP interaction with UFD1 (Z. H. Li et al., 2017) .
Human UBXN7 mediates VCP interaction with the transcription factor HIF1α that
is actively ubiquitylated in normoxic cells by a CUL2-based E3 ligase, CRL2. UBXN7
interaction with cullins is independent of ubiquitin- and substrate-binding. Instead, it
relies on the ubiquitin-interacting motif (UIM) in UBXN7 that directly engages the NEDD8
modification on cullins. It leads to accumulation of HIF1α, a CUL2 substrate that uses
UBXN7/VCP as a ubiquitin-receptor on its way to proteasome-mediated degradation.
Also, HIF1α carrying long ubiquitin-chains can recruit alternative ubiquitin-receptors,
lacking VCP's ATP-dependent segregase activity. Thus by sequestering CUL2 in its NEDDlated form, UBXN7 negatively regulates the ubiquitin-ligase activity of CRL2, and this
might prevent recruitment of ubiquitin-receptors other than VCP to nuclear HIF1α
(Bandau et al., 2012) .
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1.3.9 UBXN8

HBV integration into the human genome has been considered as one of the major
causative factors to hepato-carcinogenesis. Analysis of in hepatocellular carcinoma
tissues revealed that UBXN8 was significantly down-regulated, particularly the tissue with
HBV integration within the intron of UBXN8. Further, the tumor suppressive activity of
UBXN8 is dependent on a cell cycle negative regulator tumor protein 53 (TP53). Thus,
UBXN8 is identified as a new tumor suppressor candidate (X. Li et al., 2014) .
Mouse UBXN8 expression was found to be highly tissue-specific and abundant in
gonads. In testes, it is expressed in post-meiotic round spermatids, whereas in ovaries it is
expressed in granulosa cells. UBXN8 associates directly with VCP via its UBX domain. It
was shown that UBXN8 is a transmembrane protein that localizes to the ER membrane
with its UBX domain facing the cytoplasm. Knock-down of UBXN8 expression in human
cells leads to a decreased association of VCP with the ER membrane and concomitantly a
slow degradation of misfolded ER-derived proteasome substrates. Thus, UBXN8 tethers
VCP to the ER membrane for efficient ER-associated degradation (Madsen et al., 2011) .

1.3.10 UBXN9

UBXN9 interact directly with VCP and also exhibit species, mutation and ATPdependent differences in the binding affinities. Also, UBXN9 efficiently disassembled wild-
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type, but to a lesser extent, mutant VCP hexamers into monomers (Rijal et al., 2016) .
Another group found similar observations that UBXN9 promotes VCP hexamer
disassembly, resulting in the formation of stable VCP-UBXN9 heterotetramers. An
extended UBX domain (eUBX) in UBXN9 is critical for this association. The overproduction
of UBXN9 disrupts VCP hexamer function in ERAD, and that engineered eUBX
polypeptides can induce cell death, providing a rationale for developing anti-cancer
polypeptide inhibitors that may target VCP activity (Arumughan et al., 2016) .
Alveolar soft part sarcoma (ASPS) is a rare tumor. In a study, UBXN9 -TFE3 fusion
transcripts were observed in all 12 ASPS case and determined as its oncogenic significant
fusion product. The UBXN9-TFE3 fusion replaces the N-terminal portion of TFE3 by the
fused UBXN9 sequences while retaining the TFE3 DNA-binding domain, implicating
transcriptional deregulation in the pathogenesis of this tumor (Ladanyi et al., 2001) .

1.3.11 UBXN10

UBXN10 localizes to cilia in a VCP-dependent manner, and both VCP and UBXN10
are required for ciliogenesis. Pharmacological inhibition of VCP destabilized the
intraflagellar transport B (IFT-B) complex and increased trafficking rates. Depletion of
UBXN10 in zebrafish embryos causes defects in left-right asymmetry, which depends on
functional cilia (Raman et al., 2015) .
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1.3.12 UBXN11

UBXN11/ Colon antigen-1 (COA-1) was recently identified as a novel antigen of
colorectal cancer encoded by the UBXD5 gene. UBXN11-specific and tumor-reactive T
lymphocytes were isolated from all studied colorectal cancer patients with the
progressive disease but not in patients with early-stage tumor and healthy donors,
suggesting that the immune response against this antigen is associated with the
progression of colorectal cancer. UBXN11- and tumor-specific T lymphocytes displayed a
CD3+CD4+CD69+CD45RA+ phenotype, compatible with the activated effector-type T-cell
subset, and most of them exerted cytotoxic activity against HLA-matched and UBXN11+
tumor cells. UBXN11-specific T cells could also be isolated by in vitro stimulation of
peripheral blood mononuclear cells with autologous dendritic cells loaded with tumor
lysate, suggesting that this antigen can generate a dominant immunologic response
against colorectal cancer cells. Notably, UBXN11-derived epitopes binding to HLA-A*0201
molecules elicited antigen- and tumor-specific CD8+ T-cell-mediated responses in
colorectal cancer patients (Maccalli et al., 2008) .

1.3.13 p47

p47 is a cofactor of VCP, and it is the best-studied UBXN. In the animal cells, p47 is
required to be associated with VCP for budding of cisternae from mitotic Golgi fragments.
In budding yeast cells, it is essential or the process called karyogamy/ outer membrane
43

fusion reaction (Kondo et al., 1997) . The p47 phosphorylation on Serine-140 by Cdc2
results in mitotic inhibition of the VCP/p47 pathway (Uchiyama et al., 2003) .
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Figure 8: Types of UBXNs and its domains.
UBXNa are primarily divided into two groups depending on their domain. The first group
consists of UBA-UBX domain-containing proteins and the second group consists of only
UBX domain-containing proteins As adapted from (Alexandru et al., 2008)
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Materials and methods

2.1 Materials

2.1.1 Cell lines

Human embryonic kidney 293 cells transformed with T antigen of SV40 (HEK293T,
# CRL-3216), Vero cells (monkey kidney epithelial cells, # CCL-81) were purchased from
American Type Culture Collection (ATCC) (Manassas, VA20110, USA). A 2fGTH cell line
stably expressed an ISRE-luciferase reporter. It was used previously (Jinzhu Ma et al.,
2018a) . HEK293T, Vero cells, and 2fGTH cells were grown in DMEM and trophoblast were
grown in RPMI 1640 (Gibco) supplemented with 10% FBS, glutamine, antibiotics, and
mycozap (Lonza).

2.1.2 Viruses

Encephalomyocarditis virus (EMCV, VR129-B) and Zika virus FLR strain (Cat# VR1844) were purchased from American Type Culture Collection (ATCC) (Manassas,
VA20110 USA). The Indiana strain of VSV was tagged with Green fluorescence protein
(GFP) to generate VSV-GFP. All viruses were propagated in Vero cells.
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2.1.3 Plasmid construction

FLAG-Myc-UBXN2A (Cat # MR203340), -2B (Cat# MR204884) were purchased from
Origene (Rockville, MD 20850, USA). FLAG-UBXN1 was constructed previously in our lab.
The additional FLAG-UBXNs (which include FLAG-UBXN3A, FLAG-UBXN3B, FLAG-UBXN4,
FLAG-UBXN6, FLAG-UBXN7, FLAG-UBXN8, FLAG-UBXN9, FLAG-UBXN10, FLAG-UBXN11,
P47) were a kind gift of Dr. Raymond J. Deshaies at California Institute of Technology,
USA.

2.1.4 Ligand treatment conditions

PRR ligand 100 ng of RIG-I plasmid or 4 μg/ml poly (I: C) (Invivogen #tlrI-pic) were
transfected into cells with Lipofectamine 2000. Human IFN-β (PeroTech #300-02BC-5UG)
or human IFN-λ1 (PeroTech #300-02L-5UG) were added to the growth medium without
serum at the final concentration of 10ng/ml of medium. The cells were incubated for 0,
30, 60 minutes following treatment, for the determination of JAK-STAT molecules. The
incubation was for 16-24hrs for determining the ISG mRNA levels after stimulation.

2.1.5 Lipofectamine transfection protocol

24 well plate seeded with 50,000 HEK-293T cells/well and incubated at 370 C with
5% CO2. After 16-24 hrs, cells were 50-80% confluent. The cell culture medium was
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changed to serum-free DMEM. Plasmids with required concentration were added to
serum-free DMEM in 1.5 ml microcentrifuge tube. In another 1.5 ml microcentrifuge
tube, Lipofectamine 2000 reagent was added to serum-free DMEM. Both mixtures were
incubated for 5 minutes separately and then added and incubated for 20 minutes at room
temperature. The prepared DNA + Lipofectamine 2000 transfection mix was added to
cells in a dropwise manner. Cells were incubated at 370C with 5% CO2. After 6-10 hours,
the culture medium was changed to DMEM with 10% serum.

2.1.6 Virus infection conditions

The viruses were allowed to infect cells for two hours in the serum-free medium;
the cells were then washed with 1× phosphate-buffered saline (PBS) once and incubated
with pre-warmed medium with 10% serum. The MOI and infection conditions were
specified for each experiment in the figure legend.
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2.2 Methods
2.2.1 Dual-Luciferase reporter assay
2.2.1.1 Rationale

Dual Luciferase reporter system is developed to measure renilla and firefly
luciferase activity in the same sample (Figure 9) (Grentzmann et al., 1998) . Firefly
luciferase is a 61kDa and Renilla luciferase a 36kDa protein. Both are monomeric, and
neither requires post-translational processing so that they can function as genetic
reporters immediately upon translation.
The activity of the primary reporter gene is proportional to the specific treatment,
while the control reporter gene provides internal control to normalize results. The
advantage of dual glow system is the establishment of the internal control, which reduce
sample variation by reducing false negative or false positive readouts caused by nonspecificity (Promega, 2019) .

52

Figure 9: The principle of a dual nonsecreted luciferase reporter assay.
Transfection of two reporter plasmid vectors consist of the firefly luciferase gene
sequence downstream to target promoter (ISRE in our system), and the Renilla luciferase
gene sequence with the constitutive promoter sequence as a control. The promoter
region regulates the expression of the luciferase genes in living cells. Firefly luciferase
protein catalyzes the externally provided substrate luciferin in the presence of Mg 2+ and
ATP to produce a yellow-green light. This reaction is stopped by the inhibitor, and
subsequent renilla luciferase activity is measured as proportional to the production of
blue light by catalysis of substrate coelenterazine. As adapted from (Ohmiya)
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2.2.1.2 Protocol

24 well plate seeded with 50,000 HEK-293T cells/well. After 16-24 hrs, 50-80%
confluent HEK293T cells were transfected with Calcium phosphate transfection method.
Briefly, a combination of 3 plasmids including 100 ng of pGL3-ISRE luciferase reporter
(firefly luciferase; experimental reporter) plasmid, 10ng of Actin-Renilla reporter (renilla
luciferase; internal control), and each UBXN expressing plasmid are mixed with 100µL
0.25M CaCl2 and incubated at room temperature for 15 minutes. Then 100µL 2xHBS
added dropwise with aeration. They were incubated at room temperature for 20 minutes.
200µL of plasmid- Calcium phosphate Complex is added to each well. After 10-12 hours
10ng/mL hIFNβ or hIFNλ was added. 16 hrs after transfection, luciferase activity was
measured using a Promega Dual- Glow Luciferase assay system (Cat# E2920).
Briefly, media were removed from multiwell plates. Cells were washed with 500
µL cooled 1X PBS and lysed by adding 50 µL of 1X passive lysis buffer to each well. To 5 µL
of cell lysate is aliquoted to 1.5 mL microcentrifuge tube, 30 µL Dual-Glo Luciferase
Reagent was added, and firefly luciferase activity was measured in terms of luminescence
produced by a luminometer. To the same sample, 30 µL STOP-Glo Luciferase Reagent was
added and mixed, and Renilla luciferase activity was measured in terms of luminescence
produced by a luminometer.

2.2.1.3 Data analysis
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The luminescence values and the ratio of luminescence from the ISRE reporter to
luminescence from the control Renilla reporter were noted. This ratio was normalized to
the ratio of a control well of non-stimulated vector control. Relative Response Ratios was
calculated from IFN stimulated Vector samples to the IFN stimulated UBXNs samples.

2.2.2 Biochemical Assay for IFN-I bioavailability

IFN-I concentration in the cell culture supernatant was measured by 2fGTH
reporter cell line. This cell line stably expresses the ISRE-luciferase reporter, which is
activated in proportion to IFN concentration (Jinzhu Ma et al., 2018a) . Briefly, 1 ×
105 2fGTH cells were seeded in each well of 24-well plate and grown in complete DMEM
supplemented with 10% FBS and antibiotics/antimycotics at 37°C, 5% CO 2overnight. Two
hundred microliters of samples of pre-stimulated HEK293T culture medium were added
to the 2fGTH-ISRE-Luc cells and incubated at 37°C, 5% CO2 for ten hours. A serial two-fold
dilution of recombinant human IFN-β served as positive controls and was used for a
standard curve plot. Unstimulated HEK293T cell culture medium served as a negative
control. After ten hours of stimulation, luciferase activity was measured by Luciferin
substrate (Promega).
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2.2.3 Generation of gene knockout cell lines with CRISPR-Cas9 technology
2.2.3.1 Background

CRISPR technology was used to generate knockout cells (Figure 10). We coexpressed an endonuclease- Cas9 and a guide RNA (gRNA) specific to the UBXN6 gene
exon2 sequence. The 20 nucleotide DNA sequence of the target was chosen based on two
characteristics:

1. The target sequence was unique compared to the rest of the genome.
2. A Protospacer Adjacent Motif (PAM)/ NGG sequence was present immediately
adjacent to the chosen target sequence.
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Figure 10: The mechanism of CRISPR-Cas9 technology.
The expressed Cas9 protein and gRNA form a ribonucleoprotein complex through
interactions between the gRNA scaffold and surface-exposed positively-charged grooves
on Cas9. The Cas9 + gRNA complex undergoes a conformational change, in which the
active Cas9 bind to DNA, whereas the spacer region of the gRNA, remains free to interact
with target DNA. The Cas9 nuclease has two functional endonuclease domains: RuvC and
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HNH. Cas9 undergoes a second conformational change upon target binding that positions
the nuclease domains to cleave opposite strands of the target DNA. The result of Cas9mediated DNA cleavage is a double-strand break (DSB) within the target DNA (∼3-4
nucleotides upstream of the PAM sequence). The resulting DSB is then repaired by one of
two general repair pathways:
1. The efficient but error-prone non-homologous end joining (NHEJ) pathway
2. The less efficient but high-fidelity homology-directed repair (HDR) pathway
The NHEJ repair pathway is the most effective repair mechanism, and it frequently causes
small nucleotide insertions or deletions (indels) at the DSB site. The randomness of NHEJmediated DSB repair has important practical implications because a population of cells
expressing Cas9 and a gRNA will result in a diverse array of mutations.
In most cases, NHEJ gives rise to small indels in the target DNA that result in amino acid
deletions, insertions, or frameshift mutations leading to premature stop codons within
the open reading frame (ORF) of the targeted gene. The typical result is a loss-of-function
mutation within the targeted gene. As adapted from (Addgene, 2019)
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2.2.3.2 Protocol:
Well established CRISPR-Cas9 protocol was used to create gene knockout (Figure
11) (Ran et al., 2013)

2.2.3.2.1 Designing gRNA:
The 20 nucleotides long gRNA specific to the UBXN6 gene exon2 sequence were
designed based on the unique target sequence and PAM/ NGG sequence adjacent to
target sequence (Table 2).
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Table 2: Two sequences of human UBXN6 gene at exon-2 were targeted by designing a
pair of gRNA.

Gene

gRNA Primer sequence

UBXN6_CRISPR-F1

CAC CGT CGG ATG GTG TCC TGC GAT G

UBXN6_CRISPR-R1

AAA CCA TCG CAG GAC ACC ATC CGA C

UBXN6_CRISPR-F2

CAC CGG CTG GTT GGG CTT CTC TTT G

UBXBN6_CRISPR-R2 AAA CCA AAG AGA AGC CCA ACC AGC C
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2.2.3.2.2 Cloning

The primer pairs were annealed and cloned into Lenti-CRISPR V2 plasmid
separately (Sanjana et al., 2014) . The cloned g-RNA was confirmed by sequencing using
the LKO.1 primer with the sequence 5'-GAC TAT CAT ATG CTT ACC GT-3.'

2.2.3.2.3 Production of packaging Lentivirus particles:

The g-RNA- Lenti-CRISPR V2 vector was co-transfected into HEK293T cells with the
packaging plasmids pCMV-VSV-G (Addgene# 8545) and psPAX2 (Addgene# 12260) in ratio
1:2:2. The first harvest of supernatant Lentivirus particles was collected after two days of
transfection. The second harvest was after 4 days of transfection. The medium was
centrifuged, and the supernatant was stored at -80o C.

2.2.3.2.4 Transduction and selection of knock-out clone:

HEK293Tcells, trophoblasts were then transduced by lentiviral particles for three
days. The efficiency of transduction was increased by adding polybrene. The wild type
(WT) control was lentiCRISPRv2 vector only. The puromycin (1 μg/ml) selection applied to
transduced cells for both HEK293T cells and trophoblasts. The non-transduced cells died
of puromycin, while all transduced cells were survived. Immunoblotting confirmed the
successful knockout clones. For RT-PCR, the primer pair to find the gene deletion was
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designed which target the selected sgRNA sequence and the sequence 100 nucleotides
apart (Table 3).
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Table 3: The designing of primer pairs for detection of UBXN6 deletion by qPCR.
Gene
UBXN6-QPCR1-FWD
UBXN6-QPCR1-REV
UBXN6-QPCR2-FWD
UBXN6-QPCR2-REV

Primer sequence
AGG CCC ACA AAG AGA AGC
TGG GGC CCC AGG CCC GGG
GGC CCC ACA TCG CAG GAC
GGG CAG AGC CTT CCT CTC
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Figure 11: Protocol for the generation of gene knockout by CRISPR technology.
Briefly, the target-specific gRNA was designed and cloned into Lenti-CRISPR V2 plasmids.
The CRISPR-Cas9 + gRNA library was amplified and packaged into lentivirus particle and
used to transduce target cells. The transduced cells were selected by puromycin survival.
The knockout of the target gene was confirmed by immunoblotting As adapted from
(Addgene, 2019) .
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2.2.4 Reverse transcription and quantitative PCR (qPCR)

The cells were washed with 1X PBS and lysed in 350μl of RLT buffer containing βmercaptoethanol (QIAGEN RNeasy mini kit). The total RNA was extracted following the
QIAGEN RNeasy manufacturer’s instructions. Reverse-transcription of RNA into cDNA was
performed using the BIO-RAD iScript cDNA Synthesis Kit. qPCR was performed with genespecific primers and SYBR Green. Results were calculated using the –ΔΔCt method and a
housekeeping gene as an internal control. The qPCR primers were listed in the Previous
study (Yang et al., 2018) . The housekeeping gene controls were beta-actin (ACTB). These
primer sequences are listed (Table 4).
Fold induction was the change in gene expression after infection or stimulation. It
was calculated as the ratio of induced (infected/stimulated) to basal (noninfected/stimulated) levels.
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Table 4: The primers used for detection of gene expression by qPCR.

Gene
hOAS1-F
hOAS1-R
hIFIT-1-F
hIFIT-1-R
hISG15-F
hISG15-R
hIL28-F
hIL28-R
hIL29-F
hIL29-R
hTNF-F
hTNF-R
hIFNB -F
hIFNB -R
ACTB-F
ACTB-R
VSV-F
VSV-R
ZIKV-F
ZIKV-R
EMCV-F
EMCV-R

Primer sequence
AGGAAAGGTGCTTCCGAGGTAG
GGACTGAGGAAGACAACCAGGT
GCCTTGCTGAAGTGTGGAGGAA
ATCCAGGCGATAGGCAGAGATC
CTCTGAGCATCCTGGTGAGGAA
AAGGTCAGCCAGAACAGGTCGT
TCGCTTCTGCTGAAGGACTGCA
CCTCCAGAACCTTCAGCGTCAG
AACTGGGAAGGGCTGCCACATT
GGAAGACAGGAGAGCTGCAACT
CTCTTCTGCCTGCTGCACTTTG
ATGGGCTACAGGCTTGTCACTC
CAGCAATTTTCAGTGTCAGAAGCT
TCATCCTGTCCTTGAGGCAGT
ATCCTGGCCTCGCTGTCCAC
GGGCCGGACTCGTCATAC
CATGTCACTGCAAGGCCTAAGA
GGCAGTATCGTGAATTCGATGC
CCGCTGCCCAACACAAG
CCACTAACGTTCTTTTGCAGACAT
CCTCTTAATTCGACGCTTGAA
GGCAAGCATAGTGATCGAG

66

2.2.5 PCR array of human IFN-I Response

Isolated RNA was reverse transcribed using a cDNA kit. The cDNA was used on the
real-time RT Profiler PCR Array (Table 5) (QIAGEN, Cat. no. PAHS-016Z) in combination
with SYBR Green qPCR Mastermix (Cat. no. 330529). CT values were exported to an Excel
file to create a table of CT values. This table was then uploaded on to the data analysis
web portal at http://www.qiagen.com/geneglobe. Samples were assigned to controls and
test groups. CT values were normalized based on a/an Automatic selection from HKG
panel of reference genes.
The data analysis web portal was used to calculate the fold change/regulation by
the delta-delta CT method. Briefly, delta CT is calculated between the gene of interest
(GOI) and an average of reference genes (HKG), followed by delta-delta CT calculations
(delta CT (Test Group)-delta CT (Control Group)). Fold Change is then calculated using two
^ (-delta delta CT) formula. The data analysis web portal also plots scatter plot, volcano
plot, clustergram, and heat map. This data analysis report was exported from the QIAGEN
web portal at GeneGlobe.
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Table 5: The design of the PCR array plate for human IFN-I response gene.
Posi
tion
A01
A02
A03

Unigene
Hs.12341
Hs.523309
Hs.118110

Refseq
NM_001111
NM_004281
NM_004335

Symbol
ADAR
BAG3
BST2

A04
A05
A06
A07
A08
A09
A10

Hs.2490
Hs.74034
Hs.303649
Hs.514821
Hs.501497
Hs.838
Hs.171182

NM_033292
NM_001753
NM_002982
NM_002985
NM_001252
NM_005191
NM_006889

CASP1
CAV1
CCL2
CCL5
CD70
CD80
CD86

A11

Hs.238990 NM_004064 CDKN1B

A12
B01
B02
B03

Hs.701991
Hs.709456
Hs.632586
Hs.190622

B04

Hs.131431 NM_002759 EIF2AK2

B05
B06
B07
B08
B09
B10
B11
B12
C01
C02

Hs.62661
Hs.181244
Hs.77961
Hs.650174
Hs.512152
Hs.380250
Hs.532634
Hs.14623
Hs.730125
Hs.163173

NM_002053
NM_002116
NM_005514
NM_005516
NM_002127
NM_005531
NM_005532
NM_006332
NM_002038
NM_022168

C03

Hs.20315

NM_001548 IFIT1

C04

Hs.437609 NM_001547 IFIT2

C05

Hs.47338

NM_000246
NM_000567
NM_001565
NM_014314

CIITA
CRP
CXCL10
DDX58

GBP1
HLA-A
HLA-B
HLA-E
HLA-G
IFI16
IFI27
IFI30
IFI6
IFIH1

NM_001549 IFIT3

Description
Adenosine deaminase, RNA-specific
BCL2-associated athanogene 3
Bone marrow stromal cell antigen 2
Caspase 1, apoptosis-related cysteine
peptidase (interleukin 1, beta, convertase)
Caveolin 1, caveolae protein, 22kDa
Chemokine (C-C motif) ligand 2
Chemokine (C-C motif) ligand 5
CD70 molecule
CD80 molecule
CD86 molecule
Cyclin-dependent kinase inhibitor 1B (p27,
Kip1)
Class II, major histocompatibility complex,
transactivator
C-reactive protein, pentraxin-related
Chemokine (C-X-C motif) ligand 10
DEAD (Asp-Glu-Ala-Asp) box polypeptide 58
Eukaryotic translation initiation factor 2alpha kinase 2
Guanylate binding protein 1, interferoninducible
Major histocompatibility complex, class I, A
Major histocompatibility complex, class I, B
Major histocompatibility complex, class I, E
Major histocompatibility complex, class I, G
Interferon, gamma-inducible protein 16
Interferon, alpha-inducible protein 27
Interferon, gamma-inducible protein 30
Interferon, alpha-inducible protein 6
Interferon induced with helicase C domain 1
Interferon-induced protein with
tetratricopeptide repeats 1
Interferon-induced protein with
tetratricopeptide repeats 2
Interferon-induced protein with
tetratricopeptide repeats 3
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C06

Hs.458414 NM_003641 IFITM1

C07

Hs.709321 NM_006435 IFITM2

C08
C09
C10
C11

Hs.374650
Hs.37026
Hs.211575
Hs.1510

C12

Hs.529400 NM_000629 IFNAR1

D01
D02
D03
D04
D05
D06
D07
D08
D09
D10

Hs.708195
Hs.93177
Hs.682604
Hs.73010
Hs.193717
Hs.168132
Hs.654458
Hs.436061
Hs.654566
Hs.289052

NM_021034
NM_024013
NM_000605
NM_021068

IFITM3
IFNA1
IFNA2
IFNA4

IFNAR2
IFNB1
IFNE
IFNW1
IL10
IL15
IL6
IRF1
IRF2
IRF3

D11
D12
E01
E02

NM_000874
NM_002176
NM_176891
NM_002177
NM_000572
NM_000585
NM_000600
NM_002198
NM_002199
NM_001571
NM_001098
Hs.521181 629
Hs.166120 NM_001572
Hs.1706
NM_006084
Hs.458485 NM_005101

E03
E04
E05
E06

Hs.459265
Hs.207538
Hs.656213
Hs.80395

ISG20
JAK1
JAK2
MAL

E07
E08

Hs.132966 NM_000245 MET
Hs.153837 NM_002432 MNDA

E09

Hs.517307 NM_002462 MX1

E10

Hs.926

NM_002463 MX2

E11
E12

Hs.82116
Hs.54483

NM_002468 MYD88
NM_004688 NMI

NM_002201
NM_002227
NM_004972
NM_002371

IRF5
IRF7
IRF9
ISG15

Interferon induced transmembrane protein
1 (9-27)
Interferon induced transmembrane protein
2 (1-8D)
Interferon induced transmembrane protein
3
Interferon, alpha 1
Interferon, alpha 2
Interferon, alpha 4
Interferon (alpha, beta and omega) receptor
1
Interferon (alpha, beta and omega) receptor
2
Interferon, beta 1, fibroblast
Interferon, epsilon
Interferon, omega 1
Interleukin 10
Interleukin 15
Interleukin 6 (interferon, beta 2)
Interferon regulatory factor 1
Interferon regulatory factor 2
Interferon regulatory factor 3
Interferon regulatory factor 5
Interferon regulatory factor 7
Interferon regulatory factor 9
ISG15 ubiquitin-like modifier
Interferon stimulated exonuclease gene
20kDa
Janus kinase 1
Janus kinase 2
Mal, T-cell differentiation protein
Met proto-oncogene (hepatocyte growth
factor receptor)
Myeloid cell nuclear differentiation antigen
Myxovirus (influenza virus) resistance 1,
interferon-inducible protein p78 (mouse)
Myxovirus (influenza virus) resistance 2
(mouse)
Myeloid differentiation primary response
gene (88)
N-myc (and STAT) interactor
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F01
F02
F03
F04
F05

Hs.709191
Hs.524760
Hs.414332
Hs.654583
Hs.496255

F06
F07

Hs.375217 NM_002818 PSME2
Hs.349094 NM_002351 SH2D1A

F08
F09

Hs.521482 NM_003028 SHB
Hs.50640 NM_003745 SOCS1

F10

Hs.642990 NM_007315 STAT1

F11

Hs.530595 NM_005419 STAT2

F12

Hs.463059 NM_003150 STAT3

G01
G02
G03
G04
G05
G06
G07

Hs.731555
Hs.29344
Hs.522632
Hs.657724
Hs.659215
Hs.660543
Hs.87968

G08

Transmembrane protein 173
Tumor necrosis factor (ligand) superfamily,
Hs.478275 NM_003810 TNFSF10 member 10
Hs.510528 NM_003300 TRAF3
TNF receptor-associated factor 3
Hs.75516 NM_003331 TYK2
Tyrosine kinase 2
Hs.73793 NM_003376 VEGFA
Vascular endothelial growth factor A
Hs.520640 NM_001101 ACTB
Actin, beta
Hs.534255 NM_004048 B2M
Beta-2-microglobulin
Glyceraldehyde-3-phosphate
Hs.592355 NM_002046 GAPDH
dehydrogenase
Hs.412707 NM_000194 HPRT1
Hypoxanthine phosphoribosyltransferase 1
Hs.546285 NM_001002 RPLP0
Ribosomal protein, large, P0
N/A
SA_00105
HGDC
Human Genomic DNA Contamination
N/A
SA_00104
RTC
Reverse Transcription Control
N/A
SA_00104
RTC
Reverse Transcription Control

G09
G10
G11
G12
H01
H02
H03
H04
H05
H06
H07
H08

NM_000625
NM_002534
NM_002535
NM_033238
NM_002744

NM_000593
NM_182919
NM_003254
NM_003265
NM_016562
NM_138636
NM_017442

NOS2
OAS1
OAS2
PML
PRKCZ

TAP1
TICAM1
TIMP1
TLR3
TLR7
TLR8
TLR9
TMEM1
Hs.379754 NM_198282 73

Nitric oxide synthase 2, inducible
2'-5'-oligoadenylate synthetase 1, 40/46kDa
2'-5'-oligoadenylate synthetase 2, 69/71kDa
Promyelocytic leukemia
Protein kinase C, zeta
Proteasome (prosome, macropain) activator
subunit 2 (PA28 beta)
SH2 domain containing 1A
Src homology 2 domain containing adaptor
protein B
Suppressor of cytokine signaling 1
Signal transducer and activator of
transcription 1, 91kDa
Signal transducer and activator of
transcription 2, 113kDa
Signal transducer and activator of
transcription 3 (acute-phase response
factor)
Transporter 1, ATP-binding cassette, subfamily B (MDR/TAP)
Toll-like receptor adaptor molecule 1
TIMP metallopeptidase inhibitor 1
Toll-like receptor 3
Toll-like receptor 7
Toll-like receptor 8
Toll-like receptor 9
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H09
H10
H11
H12

N/A
N/A
N/A
N/A

SA_00104
SA_00103
SA_00103
SA_00103

RTC
PPC
PPC
PPC

Reverse Transcription Control
Positive PCR Control
Positive PCR Control
Positive PCR Control
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2.2.6 ELISA (enzyme-linked immunosorbent assay)

A commercial ELISA kit was used to measure the interferon levels in the cell
culture supernatants. The levels of IFN-λ2 (Cat # RHF333CK) and IFN-β (Cat# RHF842CK,
from Antigenix America, INC) were quantified. Briefly, the plate was prepared by adding
100 uL of the diluted capture antibody with 0.05M Carbonate buffer (or PBS) to
concentration 1.0 ug/mL. The plate was sealed and incubated overnight at room
temperature. All liquid was removed, and plates were washed four times using 300 uL of
wash buffer per well. After last wash, 200 uL ANTIGENIX AMERICA ELISA coating stabilizer
cat # EA150) was added and incubated for 60 minutes at room temperature. The standard
was serially diluted from 10.0 ng/mL to zero, and 100 uL of standard or undiluted samples
were added to each well in triplicate and incubated at room temperature for 2 hours. The
plate was aspirated and washed four times. 100 uL per well detection (Biotin Tracer)
antibody in the diluent to the concentration of 0.20 ug/mL was added and incubated at
room temperature for 1 hour. The plate was aspirated and washed four times. 100 uL per
well Streptavidin-HRP conjugate 1:1,000 in diluent was added and incubated for 30
minutes at room temperature. The plate was aspirated and washed four times. 100 uL
per well substrate solution was added and incubated for 10 minutes at room
temperature. 100 uL stop solution was added to stop color development. The plate was
read at @ 450 nm in ELISA plate reader spectrophotometer.
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2.2.7 Immunoblotting

Samples were prepared from cultured cells after washing with ice-cold 1X PBS.
Cold Triton lysis buffer was added to well/ plate/ flask. Lysates were kept on ice with
constant agitation for 30 minutes. The microcentrifuge tubes containing lysates were
centrifuged at 12,000 rpm for 20 minutes at 4oC. The supernatant was transferred to a
new tube, mixed with SDS loading dye with freshly added β-mercaptoethanol and used
for electrophoresis. Equal amounts of protein were loaded into the wells of the SDSPAGE gel, along with molecular weight marker. The gel was run for 1–2 h at 100 V. Next,
the proteins were transferred from gel to nitrocellulose membrane by wet transfer
method. The membrane was washed and blocked for one h at room temperature in the
1% milk as blocking buffer. The membrane was incubated with appropriate dilutions of
primary antibody in blocking buffer overnight at 4°C (Table 6). The membrane was
washed three times in TBST 10 min each and incubated with the recommended in HRPconjugated secondary antibody in blocking buffer at room temperature for one h. An
enhanced chemiluminescent (ECL) substrate (ThermoFisher Cat# 32106) was applied, and
images were acquired using darkroom development techniques.

73

Table 6: List of antibodies used for immunoblotting.
Species
reactivity

Mol
wt(kDa)

HMR

Tubulin(DM1A)

Antibody
Flag (1mg/ml)
GAPDH
(1mg/ml)

Source
mouse

Catalog number
collaborator

36

Dilution
1-1000
0.10.2µg/ml

rabbit

H M R Mk

52

1-1000

UBXD1/ UBXN6
phosphoStat1(Tyr701)

HMR

50

1-1000

mouse
rabbitpolyclonal

HM

84, 91

1-1000

rabbit

Stat1

H M R Mk

84, 91

1-1000

rabbit

sigma G9545
Cell signal
3873ing
Proteintech
14706-1-AP
Cell Signaling
9167
Cell Signaling
9172
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2.2.8 Co-immunoprecipitation.
2.2.8.1 Rationale:

ANTI-FLAG M2 Magnetic Beads (Sigma # M8823) is composed of the ANTI-FLAG
M2 monoclonal antibody attached to superparamagnetic iron impregnated, 4% agarose
beads. The M2 antibody binds to fusion proteins containing the FLAG peptide sequence
(Brizzard et al., 1994) . Additionally, the M2 antibody recognizes the FLAG octapeptide
sequence (N-Asp-Tyr-Lys-Asp-Asp-Asp-Asp-Lys-C) at the N-terminus, Met-N-terminus, or
C-terminus locations of a fusion protein in mammalian and bacterial extracts. Hence, they
are used to detect and capture of fusion proteins containing a FLAG peptide sequence by
commonly used immunoprecipitation procedures (Safarik and Safarikova, 2004) .

2.2.8.2 Sample Preparation:

1x107 HEK293T cells were transfected with either empty vector or expression
plasmids (FLAG-UBXN6) using Lipofectamine 2000. After 24 hours, transfected cells were
treated with human IFN-β (10ng/ml) for 60 minutes. The four experiemental groups were:
1. IP1-Vector control
2. IP2-Vector + IFNλ
3. IP3- FLAG-UBXN6
4. IP4- FLAG-UBXN6 + IFNλ
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Whole cell lysates were prepared from transfected cells in 1ooµl lysis buffer. The lysates
were cleared by centrifugation at 10,000g for 20min at 4°C. Whole cell lysates were
immunoprecipitated with FLAG antibody-conjugated magnetic beads as detailed below.

2.2.8.3 Binding

The resin was thoroughly resuspended and transferred to a microcentrifuge tube.
The beads were equilibrated by resuspending with five packed gel volumes of TBS (50
mM Tris HCl, 150 mM NaCl, pH 7.4) for five times. The cleared lysates were incubated
with the Beads with gentle agitation at 4°C overnight. Once the binding step was
complete, the magnetic beads were collected by placing the tube in the appropriate
magnetic separator (Promega # Z5434) and removed the supernatant. The resin beads
were washed with TBS buffer to remove all of the nonspecifically bound proteins. The
beads were washed five times in ice-cold 1X wash buffer. The bound proteins were eluted
by competition with the FLAG Peptide by adding five packed gel volumes of a solution
containing the 3X- FLAG peptide (Sigma# F 4799) in TBS buffer. The supernatants were
incubated with gentle shaking on a rotator for 30 minutes at room temperature. The
supernatants were collected by placing the tubes in the magnetic separator. The
supernatants were stored at -20o C, used for SDS-PAGE analysis with Coomassie blue
staining and sent for Mass spectrometry evaluation at the Proteomics and Metabolomics
facility, University of Connecticut, Storrs, Connecticut.
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A Thermo Q Exactive HF Orbitrap mass spectrometer coupled to a Dionex Ultimate
RSLCnano UPLC was used for the analysis at the Proteomics and Metabolomics facility,
University of Connecticut, Storrs, Connecticut. All data was processed with the MaxQuant

search algorithm and visualized with Scaffold Q+S.

2.2.8.4 Data analysis of Mass Spectrometry:

The results obtained from the Mass spectrometry evaluation identified total 522
proteins in four IP samples; denoted with their name, accession number, alternate ID,
molecular weight, protein grouping ambiguity and total spectrum count of each group.
A spectrum count is a single MS/MS spectrum that has been matched to a single
peptide sequence from any given identified protein. The acquisition method samples the
most abundant peptide ions first, so spectral counts are a rough estimate of overall
protein abundance (most abundant proteins will have the highest number of spectral
counts), with a few caveats.
The first fifty proteins, which shows highest total spectrum count were tabulated.
The total spectrum counts of bound proteins were normalized to input UBXN6 counts.
Amongst the fifty identified proteins three UBXN6-interacting proteins with the highest
normalized value were considered to hypothesized UBXN6-interacting protein under IFNλ
stimulation.
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2.2.9 Quantification of infectious viral particles by Plaque-forming assay

The 6-well plates were seeded with Vero cells in DMEM with 10% FBS, antibiotics
and glutamine so that cells were 90% confluent on the day of the assay (2.5x10 5
cells/well). The virus dilutions were made in DMEM without serum by making serial 10fold dilutions. The medium was changed to pre-warmed DMEM without serum. The
100ul/well serial dilutions of the supernatant were added to confluent Vero cells in
duplicates and incubated at 37 °C for two h. The inoculum was then replaced with warm 2
ml of DMEM complete medium with 1% SeaPlaque agarose (Cat# 50100, Lonza). Plates
were incubated at 37 °C, 5% CO2 and plaques were monitored under the microscope
each day. The second overlay of Neutral red (Sigma-Aldrich) solution and agarose were
added after incubation. Plaques were visualized as clear zones in red background.

2.2.10 RNA Interference by siRNA

1 × 105 HEK293 were plated into polyornithine-coated 24-well cell culture plates.
Sixteen hours later, cells were transfected with 40 pmol of siRNA mix directed against
human UBXN6 (three 27-mer siRNAs from Origene) or scramble control, by Lipofectamine
2000 (Invitrogen). Cells were transfected again with luciferase reporter plasmids (100 ng
ISRE-Luc and ten ng Act-Renilla per well) 36 hr after siRNA transfection. Cells were
transfected with ∆RIG-I plasmids 48 hr after siRNA transfection. Cells were washed gently
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with PBS and lysed for Dual Glow Luciferase assay following the manufacturer’s
instructions (Promega) 16 hr after infection.

2.3 Graphing and statistics

Graph Pad Prism 7 software was used for graphs and statistical analyses. For all
the graphs, data were expressed as mean ± s.e.m. A standard two-tailed unpaired
Student’s t-test was calculated in Microsoft Excel.
P values ≤ 0.05 were considered significant and denoted with **, while P values ≤
0.01 were denoted with *. The sample sizes (biological replicates), specific statistical tests
used, and the main effects of statistical analysis for each experiment were detailed in
each figure legend.
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3

Aims

Aim 1: To identify a UBXN proteins that acts as a positive regulators of RNA virusinduced innate immune responses.

Our previous studies characterized the role of UBXN1 in negative regulation of
RNA virus-induced innate immune responses and a role of UBXN3B as a positive regulator
of the innate immune response to DNA virus infections. Hence, in this project, we will
screen all UBXNs to determine the positive regulator of RNA virus-induced immune
responses.

Sub-aim 1.1: To screen for the UBXN that positively regulates type I IFN responses.
Sub-aim 1.2: To validate the UBXN screening for the role of UBXN6 in the regulation of
IFN-stimulated responses.

Aim 2: To characterize the function of UBXN6 in viral pathogenesis and host innate
immune responses.
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The screening from Aim 1 suggests that UBXN6 positively regulates RNA virusinduced IFN-I/III responses. To validate the results from the UBXN6 overexpression
studies, we evaluated IFN-I/III expression and viral replication in UBXN6 deficient cells.
Two approaches were undertaken for gene abrogation; gene knockdown by siRNA and
gene knock out by CRISPR-Cas9 technology. We have established the protocol for the
generation of knockout cells by CRISPR technology. The HEK293 and trophoblast
knockout cells (indicated as UBXN6-/- hereafter) were used to explore the function of this
gene in IFN-I/III responses and viral replication.

Sub-aim 2.1: To determine the role of UBXN6 in host immune responses by siRNA
knockdown of UBXN6.
Sub-aim 2.2: To generate UBXN6 knockout in HEK293 and trophoblast cells by CRISPRCas9 technology and to examine host immune responses as well as a viral infection in
knockout cells.

Aim 3: To find out the molecular mechanism by which UBXN6 resists viral infections and
regulates the immune responses.

UBXN6 was shown to induce hIFN-β-, and hIFN-λ-stimulated ISRE promoter
activity (from Aim 1-screen). This also indicates that the activity of Type I/III interferon81

induced JAK/STAT signaling pathway is enhanced by UBXN6. Hence, we hypothesize that
UBXN6 can regulate IFN- JAK-STAT signaling pathway.

Sub-aim 3.1: To test if recombinant hIFN-λ-induced ISG response is deficient in UBXN6-/cells.
Sub-aim 3.2: To identify UBXN6-interacting partners during IFN-I/III responses.
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4

Results

The roles of UBXNs in the regulation of antiviral immune responses have not been
much explored. Previous work in our lab identified UBXN1 as a negative regulator of the
RLR pathway and UBXN3B as a positive regulator of STING-mediated immune responses.
In this study, we aimed to determine the member of UBXNs as a positive regulator of RNA
virus infection-induced innate immune responses. By using an ISRE-driven luciferase
reporter assay that monitors the activity of type I/III IFN-induced JAK-STAT signaling, we
identified that UBXN6 overexpression synergized with RIG-I, IFN-β or IFN-λ to enhance
antiviral immune responses. We further used siRNA and CRISPR-Cas9 technology to
abrogate UBXN6 function, which was used to establish the function of UBXN6 in viral
infection and JAK-STAT signaling. By PCR array we found that UBXN6-deficiency led to a
reduction in type I/III IFN-induced gene expression, which was validated by qPCR. Also,
RNA virus replication was increased in UBXN6-deficient when compared to UBXN6sufficient cells, which was accompanied by a significant reduction in IFN-β and IFN-λ.
Lastly, we decoded the mechanism by which UBXN6 regulates the JAK-STAT pathway. We
observed that IFN-β-stimulated STAT1 phosphorylation was impaired in UBXN6-deficient
cells. By co-immunoprecipitation techniques and mass spectrometry analysis, we
identified that following IFN-β stimulation UBXN6 interacted with PRMT5, a protein
methyl transferase known to modify and interact with JAK1/2. Our results demonstrate
that UBXN6 positively regulates JAK1-STAT1/2 signaling to combat viral infections.

83

4.1 Aim 1: To identify a member of UBXN proteins as a positive regulator of
RNA virus-induced innate immune responses.

Our previous studies characterized the role of UBXN1 in negative regulation of
RNA virus-induced innate immune responses and a role of UBXN3B as a positive regulator
of the innate immune response to DNA virus infections. Hence, in this project, we will
screen all UBXNs to determine the positive regulator of RNA virus-induced immune
responses.

4.1.1.1 Sub-aim 1.1: To screen for the UBXN that positively regulates type I IFN
responses.

We performed a screening in human embryonic kidney 293 cells transformed with
T antigen of SV40 (HEK293T) cells for UBXNs that enhanced ∆RIG-I-stimulated ISRE
reporter activity. ∆RIG-I is the 2CARD domain open conformation of RIG-I. It is
constitutively active. ∆RIG-I stimulated a robust ISRE activity in vector control and UBXN6
enhanced ISRE by ~2 times compared to the treated vector control. UBXN6 was the only
UBXN that potentiated the RIG-I-induced interferon effect (Figure 12). Next, we screened
the anti-RNA virus activity of all known UBXNs using VSV as a model RNA virus, which
specifically stimulate RIG-I signaling. Amongst all tested UBXNs, overexpression of UBXN6
repressed VSV replication most dramatically as identified by Western blotting of VSV-G
protein (Figure 13).
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Figure 12: Ectopic expression of UBXN6 enhances RIG-I- induced IFN-I response.
(A) Quantification of ISRE promoter activities by a Dual-Luciferase assay in HEK293T cells
transfected with either 100ng of vector or 100ng of individual FLAG-UBXN plasmids together with
reporter plasmids 16hr after ∆RIG-I transfection.
The immunoblot of whole cell lysates depicts the expression levels of FLAG-UBXN proteins, and αTubulin serves as a housekeeping protein control.
Data represent the mean ± SEM (n = 3), Student’s t-Test: two tailed distribution, two-sample
unequal variance (*p < 0.05; ** p < 0.01)
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UBXN11
p47
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Figure 13: Immunoblot of VSV-G in the whole cell lysates prepared from HEK293T cells.
Cells were transfected with either vector or individual FLAG-UBXN plasmid and infected with VSVGFP. Actin serves as a housekeeping protein control. The results are representative of 2
independent experiments.
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4.1.1.2 Sub-aim 1.2: To validate the UBXN screening for the role of UBXN6 in the
regulation of IFN stimulated responses.

The primary immune response in the innate immunity is characterized by viral
RNA recognition by RLRs. This recognition is transduced downstream to generate IFNI/IIIs. The secreted IFN-I/IIIs further act on IFN receptor-bearing cells to activate JAK-STAT
signaling, which stimulates several hundreds of ISGs to interfere with viral processes
directly and also augmentIFN-I/III production. The activation of primary IFN-I and
secondary JAK-STAT pathways was measured by total ISRE activity. Hence, we performed
another screening in human embryonic kidney 293 cells transformed with T antigen of
SV40 (HEK293T) cells for UBXNs that enhanced type I/III IFN- stimulated response
element (ISRE) reporter activity. We observed that expression of UBXN6 increased basal
ISRE by ~2.5 times compared to the empty vector control (Figure 14A). Both recombinant
IFN-β and IFN-λ stimulated a robust ISRE activity (Vector + IFN v.s Vector alone) and
interestingly UBXN6 further enhanced ISRE by ~2.5-3.4 times compared to the treated
vector control, respectively (Figure 14 B, C).
The ability of UBXN6 to activate ISRE was dose-dependent (Figure 15A). We
further confirmed the ISRE reporter assay by quantitative reverse transcription PCR (q-RTPCR). UBXN6 potentiated the mRNA expression of two well-established ISGs, including
OAS1A and ISG15 (Figure 15B, C). These results demonstrate that UBXN6 is a unique
UBXN that regulates optimal JAK-STAT activity.
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Figure 14: Ectopic expression of UBXN6 enhances recombinant IFN induced ISRE
activity.
(A) Quantification of ISRE promoter activities by Dual-Luciferase assay in HEK293T cells
transfected with either 100ng of vector or 100ng of individual FLAG-UBXN plasmids.
The immunoblot of whole cell lysates depicts the expression levels of FLAG-UBXN proteins, and αTubulin serves as a housekeeping protein control.
(B) Quantification of ISRE promoter activities by Dual-Luciferase assay in HEK293T cells
transfected with either 100ng vector or 100ng individual FLAG-UBXN plasmids 16hr after 10ng/ ml
of human IFN- λ1 stimulation.
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(C) Quantification of ISRE promoter activities by Dual-Luciferase assay in HEK293T cells
transfected with either 100ng vector or 100ng individual FLAG-UBXN plasmids 16hr after 10ng/ ml
of human IFN- β1 stimulation.
Data represent the mean ± SEM (n = 3), Student’s t-Test: two tailed distribution, two-sample
unequal variance (** p < 0.01)
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Figure 15: Ectopic expression of UBXN6 enhances IFN-I/III-induced ISRE activity and ISG
expression in a dose-dependent manner.
(A) Quantification of ISRE promoter activities by Dual-Luciferase assay in HEK293T cells
transfected with either increasing doses of vector or increasing doses of FLAG-UBXN6 plasmid
16hr after 10ng/ ml of human IFN-λ stimulation.
(B, C) mRNA expression of interferon-stimulated gene ISG15 and OAS1A 16hrs after IFN-β
stimulation as quantified by qPCR analysis.
Data represent the mean ± SEM (n = 3), Student’s t-Test: two tailed distribution, two-sample
unequal variance (*p < 0.05; ** p < 0.01; *** p < 0.001)
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4.2 Aim 2: To characterize the function of UBXN6 in viral pathogenesis and host
innate immune responses.

The screening from Aim 1, I hypothesized that UBXN6 positively regulates RNA
virus-induced IFN-I/III responses. To validate the results from the UBXN6 overexpression
studies, we evaluated IFN-I/III expression and viral replication in UBXN6 deficient cells.
Two approaches were undertaken for gene silencing; gene knockdown by siRNA and gene
knockout by CRISPR-Cas9 technology. We have established the protocol for the
generation of knockout cells by CRISPR technology. The HEK293 and trophoblast
knockout cells (indicated as UBXN6-/- hereafter) were used to explore the function of this
gene in IFN-I/III responses and viral replication.

4.2.1 Sub-aim 2.1: To determine the role of UBXN6 in host immune responses by
siRNA knockdown of UBXN6.

We depleted UBXN6 by three individual siRNAs against UBXN6 and MAVS as a
control, followed by transfection with ∆RIG-I. We observed a moderate decrease in ISRE
activity in UBXN6-depleted cells (Figure 16A). The knockdown efficiency of specific siRNA
was about 50% (Figure 16B). Hence, we next used a mixture of all three siRNA for
transfecting HEK293. We overexpressed MDA5, MAVS, and TBK1 of the RLR pathway to
activate IFNB1 transcription in UBXN6-depleted cells. We observed a nonsignificant
decrease in ISRE activity in UBXN6-depleted cells. Also, the IFNB1 mRNA levels were not
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significantly reduced in UBXN6-depleted cells (Figure 17), suggesting that UBXN6 is not
essential for RLR signaling.
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Figure 16: RNA interference of UBXN6 moderately affects RIG-I-induced ISRE activity.
(A) Quantification of ISRE promoter activities by Dual-Luciferase assay. HEK293T cells were
transfected with either scrambled (control) or UBXN6-specific siRNA, and after 48 hours the cells
were transfected again with either vector or ∆ RIG-I and reporter plasmids. Luciferase activity was
measured 16 hrs after the second transfection.
(B) Quantification of siRNA knockdown efficiency as measured by qPCR using UBXN6 specific
primers.
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Figure 17: RNA interference of UBXN6 modestly affects the primary RLR pathway.
(A) Quantification of ISRE promoter activities by Dual-Luciferase assay in HEK293T cells
transfected with either scrambled (control) or UBXN6 specific siRNA and after 48 hours
transfected again with either vector or MAVS, TBK1, IRF3-5D.
Quantification of siRNA knockdown efficiency as measured by qPCR using UBXN6 specific primers.
(B) Expression of IFNB1 in whole cell lysate from (A) as quantified by qPCR.
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4.2.2 Sub-aim 2.2: To generate UBXN6 knockout in HEK293 and trophoblast cells by
CRISPR-Cas9 technology and to examine host immune response as well as a viral
infection in UBXN6 knockout cells.

We next generated UBXN6 knockout in HEK293T and human trophoblasts cell
lines using the CRISPR-Cas9 technology. Western blotting shows successful loss of UBXN6
protein expression (Figure 18).

Thus, the knockout efficiency at protein level was

established.
Next, we employed two models of RNA viruses, VSV and EMCV, to study the
UBXN6 antiviral function. Both viruses induce IFN-I/III and ISGs primarily via the RLRs. A
transcriptional unit encoding green fluorescent protein (GFP) is incorporated into the VSV
genome upstream of the L polymerase to facilitate viral detection by fluorescence
microscopy (Dalton and Rose, 2001) . UBXN6-/- cells produced more intracellular VSVGFP as observed by Fluorescent microscopic images (Figure 19). Consistently, UBXN6-/cells produced more intracellular VSV RNA as measured by qPCR and increased
extracellular infectious viral particles than UBXN6+/+ cells as quantified by plaque assay
(Figure 20). IFN-β and IFN-λ concentrations produced by UBXN6-/- cells were much lower
than UBXN6+/+ cells in VSV infected cells (Figure 21).
Similar results were noted with EMCV infection. UBXN6-/- cells produced more
intracellular EMCV RNA as measured by qPCR and increased extracellular infectious viral
particles than UBXN6+/+ cells as quantified by plaque assay (Figure 22).
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Figure 18: Abrogation of UBXN6 protein in trophoblast and HEK.
Immunoblots showing UBXN6 and housekeeping Tubulin in UBXN6+/+, UBXN6-/- 1 and UBXN6-/- 2
trophoblast and HEK293T cells.
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Figure 19: UBXN6 interferes with VSV infection.
Fluorescent microscopic images of UBXN6+/+, UBXN6-/- 1 and UBXN6-/- 2 trophoblasts infected with
VSV-GFP (MOI=0.01) for 12 hrs. Objective 5x, scale bar 10 μm.
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Figure 20: Viral replication is increased in UBXN6-/- trophoblasts.
(A) Quantification of intracellular VSV RNA at 12 hours after infection by qPCR.
(B) Quantification of the viral titers at 12hrs after VSV infection by plaque assay.
Data represent the mean ± SEM (n = 3), Student’s t-Test: two tailed distribution, two-sample
unequal variance (*p < 0.05; ** p < 0.01). All experiments were repeated 3 times.
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Figure 21: IFN-I/III induction by VSV is impaired in UBXN6-/- trophoblasts.
(A) ELISA of IFN-β1 secreted from UBXN6+/+, UBXN6-/- 1 and UBXN6-/- 2 trophoblasts 0, 12, and 24
hours after VSV infection.
(B) ELISA of IFN-λ2 secreted from UBXN6+/+, UBXN6-/- 1 and UBXN6-/- 2 trophoblasts 0, 12, and 24
hours after VSV infection.
Data represent the mean ± SEM (n = 3), Student’s t-Test: two tailed distribution, two-sample
unequal variance (*p < 0.05; ** p < 0.01)
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(A) Quantification of intracellular viral RNA at 12 hours after infection by qPCR.
(B) Quantification of the viral titers at 12 hrs after infection by plaque assay.
Data represent the mean ± SEM (n = 3), Student’s t-Test: two tailed distribution, two-sample
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4.3 Aim 3: To find out the molecular mechanism by which UBXN6 resists viral
infections and regulates the immune responses.

UBXN6 was shown to induce hIFN-β-, and hIFN-λ-stimulated ISRE promoter
activity (from Aim 1-screen). This also indicates that the activity of Type I/III interferoninduced JAK/STAT signaling pathway is enhanced by UBXN6. Hence, we hypothesize that
UBXN6 can regulate IFN- JAK-STAT signaling pathway.

4.3.1.1 Sub-aim 3.1: To test if recombinant hIFN-λ-induced ISG response is deficient in
UBXN6-/- cells.

We analyzed the expression of 84 genes related to IFN-I/III responses by PCR array
in UBXN6+/+ and UBXN6-/-trophoblasts (Table 7). The fold change with each gene was
shown in table 1. The volcano plot, heat map, and cluster-grams were used to identify
changes in gene expression (Figure 23 A, B, D). Expression of ~20 ISGs including wellcharacterized IFIT1, OAS1/2, IFITM1, ISG15 and DDX58 (encodes RIG-I) was >1.5 fold
lower in UBXN6-/- than UBXN6+/+ cells treated with recombinant IFN-λ for 6 hours. Three
genes (IL6, VEGF, IFNE) that are not conventional ISGs were upregulated (Figure 23 C).
The reduction in IFIT1 and OAS1 expression in HEK293 and trophoblasts was further
validated by qPCR (Figure 24).

101

Table 7: The relative fold changes in all the tested genes from human IFN-I PCR array
from UBXN6+/+ and UBXN6-/- 2 trophoblast cells 6hrs after 10ng/mL IFN-λ1 treatment.
The down-regulated genes are highlighted in blue, up-regulated in red.

Gene
Symbol
ADAR
BAG3
BST2
CASP1
CAV1
CCL2
CCL5
CD70
CD80
CD86
CDKN1B
CIITA
CRP
CXCL10
DDX58
EIF2AK2
GBP1
HLA-A
HLA-B
HLA-E
HLA-G
IFI16
IFI27
IFI30
IFI6
IFIH1
IFIT1
IFIT2
IFIT3
IFITM1
IFITM2
IFITM3
IFNA1
IFNA2
IFNA4
IFNAR1
IFNAR2
IFNB1
IFNE
IFNW1
IL10
IL15

Fold Change (UBXN6-//UBXN6+/+)
Fold

95% CI

P
value

0.89

( 0.61, 1.17 )

0.480

1.24

( 0.94, 1.53 )

0.159

1.29

( 0.97, 1.60 )

0.110

0.88

( 0.67, 1.08 )

0.50

Gene
Symbol

Fold Change (UBXN6-//UBXN6+/+)
Fold

95% CI

P
value

IL6

3.48

( 2.71, 4.26 )

0.000

IRF1

0.84

( 0.61, 1.07 )

0.287

IRF2

1.24

( 0.91, 1.57 )

0.191

0.336

IRF3

1.20

( 0.86, 1.55 )

0.323

( 0.40, 0.61 )

0.010

IRF5

1.28

( 0.57, 1.99 )

0.455

0.69

( 0.57, 0.81 )

0.010

IRF7

0.54

( 0.36, 0.73 )

0.051

0.93

( 0.73, 1.13 )

0.536

IRF9

0.86

( 0.60, 1.12 )

0.377

1.09

( 0.84, 1.34 )

0.529

ISG15

0.31

( 0.22, 0.40 )

0.010

0.95

( 0.56, 1.33 )

0.740

ISG20

0.39

( 0.29, 0.49 )

0.008

0.97

( 0.57, 1.38 )

0.993

JAK1

1.03

( 0.82, 1.24 )

0.859

1.02

( 0.70, 1.34 )

0.990

JAK2

1.14

( 0.86, 1.42 )

0.394

1.02

( 0.63, 1.40 )

0.926

MAL

1.03

( 0.62, 1.43 )

0.949

0.87

( 0.56, 1.18 )

0.406

MET

0.94

( 0.66, 1.22 )

0.656

1.08

( 0.34, 1.82 )

0.915

MNDA

0.84

( 0.59, 1.08 )

0.283

0.39

( 0.31, 0.47 )

0.005

MX1

0.65

( 0.44, 0.86 )

0.049

0.68

( 0.51, 0.85 )

0.066

MX2

0.33

( 0.25, 0.40 )

0.005

0.63

( 0.49, 0.78 )

0.037

MYD88

0.97

( 0.67, 1.28 )

0.780

0.90

( 0.65, 1.16 )

0.493

NMI

0.72

( 0.57, 0.87 )

0.053

0.66

( 0.43, 0.89 )

0.110

NOS2

1.06

( 0.81, 1.32 )

0.703

0.86

( 0.64, 1.08 )

0.322

OAS1

0.43

( 0.36, 0.50 )

0.003

0.97

( 0.62, 1.32 )

0.797

OAS2

0.35

( 0.24, 0.46 )

0.015

0.72

( 0.58, 0.87 )

0.053

PML

0.52

( 0.38, 0.67 )

0.021

0.63

( 0.42, 0.84 )

0.079

PRKCZ

0.99

( 0.68, 1.31 )

0.881

1.02

( 0.68, 1.36 )

0.957

PSME2

1.07

( 0.80, 1.35 )

0.713

0.29

( 0.17, 0.41 )

0.023

SH2D1A

1.12

( 0.80, 1.44 )

0.514

0.56

( 0.40, 0.72 )

0.035

SHB

1.18

( 0.94, 1.43 )

0.198

0.20

( 0.14, 0.26 )

0.006

SOCS1

0.96

( 0.77, 1.15 )

0.676

0.32

( 0.23, 0.40 )

0.008

STAT1

0.58

( 0.41, 0.76 )

0.044

0.30

( 0.20, 0.40 )

0.016

STAT2

0.64

( 0.46, 0.83 )

0.076

0.44

( 0.35, 0.53 )

0.007

STAT3

1.02

( 0.76, 1.29 )

0.973

0.81

( 0.66, 0.97 )

0.115

TAP1

0.68

( 0.49, 0.86 )

0.079

0.71

( 0.56, 0.87 )

0.064

TICAM1

1.12

( 0.86, 1.38 )

0.433

1.20

( 0.86, 1.54 )

0.299

TIMP1

0.79

( 0.58, 1.00 )

0.186

1.04

( 0.54, 1.54 )

0.782

TLR3

1.26

( 0.90, 1.63 )

0.178

1.28

( 0.95, 1.62 )

0.135

TLR7

0.90

( 0.19, 1.61 )

0.700

0.90

( 0.69, 1.11 )

0.416

TLR8

1.04

( 0.69, 1.40 )

0.740

1.08
1.43
1.59
1.07

(
(
(
(

)
)
)
)

0.712
0.123
0.064
0.573

TLR9
TMEM173
TNFSF10
TRAF3

1.05
0.71
0.95
0.92

(
(
(
(

)
)
)
)

0.796
0.064
0.819
0.580

1.23

( 0.50, 1.96 )

0.546

TYK2

1.01

( 0.70, 1.32 )

0.986

0.87

( 0.69, 1.05 )

0.276

VEGFA

1.69

( 1.16, 2.21 )

0.042

0.79,
0.92,
0.99,
0.77,

1.36
1.94
2.18
1.37
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Figure 23: PCR array of IFN response genes in UBXN6+/+ and UBXN6-/- 2 trophoblast cells
6hrs after IFN-λ1 treatment.
(A) The volcano plot of relative fold change in all the tested genes.
(B) The heat map of relative fold change in all the tested genes.
(C) The bar graph of genes with a 1.5 or more-fold change in the expression (upregulation/
downregulation).
(D) The cluster-gram of relative fold change in all the tested genes.
Data represent the mean ± SEM (n = 3), Student’s t-Test: two tailed distribution, two-sample
unequal variance (*p < 0.05; ** p < 0.01)
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Figure 24: UBXN6 is critical for IFN-λ1 induced ISGs production in trophoblasts.
(A) mRNA expression of IFIT1 and OAS1A at 0, 6, 12, 24 hrs after IFN-λ1 treatment in UBXN6+/+ and
UBXN6-/- 1 HEK293 cell.
(B) mRNA expression of IFIT1 and OAS1A at 0, 6, 12, 24 hrs after IFN-λ1 treatment in UBXN6+/+ and
UBXN6-/- 2 trophoblasts.
Data represent the mean ± SEM (n = 3), Student’s t-Test: two tailed distribution, two-sample
unequal variance (*p < 0.05; ** p < 0.01)

106

4.3.2 Sub-aim 3.2: To identify the molecular mechanism by which UBXN6 regulates
IFN-I/III responses.

As the data mentioned above established the role of UBXN6 in positive regulation
of IFN-I/III responses, we next investigated the mechanism by which it acts on the JAKSTAT pathway.

The STAT1 phosphorylation was significantly reduced in UBXN6-/-

trophoblast than UBXN6+/+ cells treated with recombinant IFN-λ for 60 minutes (Figure
25).
Next, we performed immune-precipitation and mass spectrometry analysis to
identify the UBXN6-interacting protein, which could be helpful for us to pinpoint the
molecular mechanism (Table 8). Consistent with a previous report (Alexandru et al., 2008)
UBXN6 bound to VCP with the highest affinity. Intriguingly, UBXN6 also pull-down CFL and
PRMT5 with/without IFN-λ treatment. IFN-λ treatment slightly increased UBXN6PRMT5/CFL/VCP interaction. Of great interest, PRMT5 is an arginine methyltransferase
that interacts with JAK1/2-TYK2 (Pollack et al., 1999) . It is thus possible that UBXN6 could
regulate JAK1-STAT1/2 signaling via PRMT5.
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Figure 25: UBXN6 regulates STAT1 phosphorylation.
Immunoblot of p-STAT1 and STAT1 in the whole cell lysates of UBXN6+/+ and UBXN6-/- 2
trophoblasts after 60 minutes of treatment with 10ng/ml IFNβ.
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Table 8: Identification of UBXN6-interacting proteins by immunoprecipitation and mass
spectrometry analysis.
HEK293T cells were transfected with either vector or FLAG-UBXN6 plasmid and treated with
human IFN-β (10ng/ml) for 60 minutes. Whole cell lysates were immunoprecipitated with FLAG
antibody-conjugated magnetic beads and the bound proteins were identified by mass
spectrometry t. The total spectrum counts of bound proteins were normalized to input UBXN6
counts. Fifty identified proteins were listed below, and three UBXN6-interacting proteins with the
highest confidence were highlighted in yellow.
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Discussion

UBXN6 belongs to a family of proteins that are putatively involved in VCPmediated cellular processes. Recent studies suggest that UBXN6 participates in ERAD
(Nagahama et al., 2009) , protein trafficking(Haines et al., 2012 ; Kirchner et al., 2013 ;
Ritz et al., 2011) , clearance of ruptured lysosomes by autophagy (Papadopoulos et al.,
2017) , degradation of mitochondrial outer membrane protein myeloid cell leukemia 1
(MCL1) in a model of Huntington's disease (Guo and Qi, 2017) . In this study, we identified
that UBXN6 is the only positive regulator of JAK-STAT signaling amongst the 13 known
UBXNs.
We present several pieces of evidence showing that UBXN6 positively regulates
the JAK1-STAT1/2 signaling pathway. First, UBXN6 overexpression potentiates ISG
induction by recombinant IFN-β or IFN-λ, which activates JAK1-STAT1/2 signaling via their
respective receptors. Second, ISG expression and STAT1 phosphorylation stimulated by
IFNs is impaired in UBXN6-deficient cells. Third, IFN/ISG expression activated by polyIC
and viral infection is also reduced in UBXN6 overexpression.
Although our data suggest that UBXN6 regulates JAK1-STAT1/2 specifically, the
observations that polyIC and virus-induced type I/III expression is also reduced in the
UBXN6 deficient cells suggest a role of UBXN6 in the RLR signaling too. The two dominant
polyIC/viral RNA receptors in human trophoblasts are melanoma differentiationassociated gene 5, MDA5 (encoded by IFIH1), and retinoic acid-inducible gene-1, RIG-I
(encoded by DDX58) (J. Ma et al., 2018b) , which are also well characterized ISGs. Their
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basal levels are generally very low and need to be induced via JAK1-STAT1/2 in the
context of polyIC/virus stimulation. Thus, a deficiency in JAK1-STAT1/2 signaling may also
negatively impact primary IFN responses. Indeed, STAT1/2 deficiency in mice led to a
significant reduction in type I IFNs after dengue virus infection (Perry et al., 2011) . To
clarify this point, we overexpressed the major molecules (MDA5/MAVS/TBK1) of the RLR
pathway to activate IFNB1 transcription independently of JAK1-STAT1/2. The results
suggest that UBXN6 does not directly regulate the RLR pathway, rather directly targets
JAK1-STAT1/2. This is further substantiated by the findings that JAK1/STAT1
phosphorylation activated directly by recombinant IFN-λ1 was impaired in UBXN6-/- cells.
Next, we investigated the molecular function of UBXN6. The significant reduction
of STAT1 phosphorylation after IFN-β stimulation in UBXN6 deficient cells suggests that
UBXN6 acts upstream in the pathway. By this hypothesis, we found that UBXN6 was able
to bind to JAK-binding protein PRMT5, when over-expressed at a very low amount and
stimulated with IFN-β. PRMT5 was identified as a JAK-binding protein and involved in
arginine methyltransferase (Pollack et al., 1999) . PRMT5 was found to be involved in the
regulation of NF-κB in TRAIL-induced apoptosis by competing with TRAIL to bind to DDR4.
Another study reported that methylation of p65 subunit leads to the regulation of NF-κB
activity (J. H. Kim et al., 2016) . However, we recognize that our current dataset cannot
conclude a functional relationship between UBXN6, PRMT5, and JAK1/2. At present,
work is underway to elucidate this. We hypothesize that PRMT5 could be a dominant
negative binder of JAK1/2 and UBXN6 binding to PRMT5 directly or as a complex of
PRMT5-UBXN6-VCP (As in Figure 26) liberates JAK from the PRMT5-bound state. The free
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JAK may undergo conformational changes and expose the phosphorylation sites or may
provide docking to STAT for its activation. It is also possible that methylation or
demethylation of arginine on JAK1/2 residues may enhance JAK phosphorylation and the
downstream signaling. Thus, increased STAT phosphorylation is a possible mechanism by
which UBXN6 can positively regulate JAK-STAT signaling.
UBXN6 could also stimulate STAT phosphorylation by a PRMT5-JAK independent
mechanism. UBXN6 may interact with TYK2, which is bound to the cytoplasmic domain of
IFN receptors, resulting in enhanced kinase activity. Alternately, UBXN6-VCP complex may
degrade inhibitors of JAK-STAT signalings, such as SOCSs, PTPs, and PIAs.
Another predicted mechanism of positive regulation of JAK-STAT signaling by
UBXN6 is via IFN receptors trafficking/recycling/degradation. Following receptor agonism,
the C-terminus of IFNAR is phosphorylated, followed by its ubiquitination and
internalization. Internalization can result in degradation of the receptor, thereby reducing
membrane expression, or it can result in the recycling of the receptor without an
extended impact on membrane receptor levels. However, clathrin-mediated endocytosis
may also serve to concentrate the IFNAR receptors and signaling components, thereby
amplifying signaling (Claudinon et al., 2007) .
Many cells are responsive to type I IFNs because their receptors are ubiquitously
expressed. In contrast, type III receptors are restricted to specific cell types such as
mucosal epithelial, endothelial cells and human liver (Wack et al., 2015) . The
trophoblasts act as a primary barrier of the placenta by constitutively secreting IFN-III.
The medium from uninfected cells was found to protect nonplacental cells from Zika
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infection. Trophoblast-derived IFN-III act as a barrier to Zika infection via autocrine as well
as the paracrine mode and restrict viral entry to the fetal compartment (Bayer et al.,
2016) . Indeed, we found that increased ISG production in trophoblasts by recombinant
IFN-λ1 stimulation was impaired in UBXN6-/- cells; confirming our findings that UBXN6
positively regulates IFN-induced ISG production.
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Figure 26: A model depicting UBXN6 association with the only PRMT5 or as a complex of
PRMT5-UBXN6-VCP to act on JAK and STAT1 phosphorylation.
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Conclusion

The UBX domain-containing proteins (UBXN) are involved in various cellular
processes including ubiquitin-dependent protein degradation, vesicle fusion, and cell
cycle control. However, their role in the regulation of the innate immune pathways has
not been thoroughly explored. We demonstrate that the UBXN6 positively regulates type
I/III interferons (IFN-I/III)- induced Janus kinase/signal transducers and activators of
transcription (JAK/STAT) pathway. IFN-I/III induce expression of several ISGs through
theJAK/STAT pathway to combat viral infections.
Amongst 13 known UBXNs, ectopic expression of UBXN6 highly enhances IFN-β
and IFN-λ1-stimulated ISG. UBXN6

-/-

HEK293 and trophoblasts were deficient in ISG

production upon IFN-λ1 stimulation. Also, RNA virus replication increased in UBXN6

-/-

cells compared to UBXN6 +/+ cells, and this was accompanied by a reduction in both IFNI/III and ISG expression. The IFN responses to a dsRNA analogue polyinosinic-polycytidylic
acid were also decreased. Phosphorylation of STAT1 induced by recombinant IFN-λ1 was
impaired in UBXN6 deficient cells. These results demonstrate that UBXN6 restricts viral
infection through optimal activation of JAK1-STAT1/2 signaling.
Mass spectrometry analysis revealed the association of UBXN6 with PRMT5, a JAKbinding protein. It is suggested that binding of UBXN6 to PRMT5 affect JAK activity and its
downstream signaling. Further mechanistic studies are required to confirm the target of
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UBXN6 in JAK-STAT signaling. Also, the role of PRMT5 when associated with UBXN6 needs
to be explored in detail.
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